ahead together esg performance report global biopharma company purpose unite science technology talent get ahead disease together aim positively impact health billion people end bold ambitions patients reflected commitments growth stepchange performance company outstanding people thrive responsible business means getting ahead disease report together right way therefore need consider ceos statement environmental social governance esg impacts across everything lab patient thats esg approach embedded strategy supports sustainable performance longterm growth helps us build trust progress six focus areas deliver returns stakeholders reduce risk access operations deliver positive social impact global health health security report environment report publish performance six diversity equity inclusion esg focus areas report includes reporting ethical standards sustainability accounting standards board sasb global product governance reporting initiative gri also submit annual un global compact communication progress ungc cop appendix find public positions range issues materiality assessment public policy gskcom also publish information people disclosures gskcom including gri sasb index sustainable development goals esg reporting criteria engagement patient organisations independent limited assurance reports engagement healthcare professionals landmark year gsk following demerger trade association memberships consumer healthcare business form haleon july charitable partnerships fullyfocused biopharma company data reported excludes previous consumer healthcare business unless otherwise specified external benchmarking detailed perform key esg ratings ftsegood member ftsegood index since frequently asked investors cdp climate change b water security forests access medicines ranked st access medicines palm oil b forests timber index industry leader antimicrobial sustainalytics low risk rating resistance benchmark msci aa rating sp global corporate sustainability assessment ranked moodys esg solutions ranked nd nd pharmaceuticals industry score pharmaceuticals sector february included djsi world iss corporate rating b rating europe indices cautionary statement document may contain forwardlooking statements forwardlooking forwardlooking statements whether result new information statements give groups current expectations forecasts future events future events otherwise investors however consult additional investor identify statements fact relate disclosures group may make documents publishes strictly historical current facts use words 'anticipate ' andor files us securities exchange commission investors 'believe ' 'estimate ' 'expect ' intend ' 'plan ' 'project ' 'target ' 'will ' wherever located take note disclosures accordingly words terms similar meaning connection discussion future assurance given particular expectation met operating financial performance particular include statements investors cautioned place undue reliance forwardlooking relating future actions prospective products product approvals future statements forwardlooking statements subject assumptions inherent performance results current anticipated products sales efforts risks uncertainties many relate factors beyond expenses outcome contingencies legal proceedings dividend groups control precise estimate group cautions investors payments financial results accordance legal number important factors including report could cause actual regulatory obligations including market abuse regulations uk results differ materially expressed implied forward listing rules disclosure guidance transparency rules looking statement financial conduct authority group undertakes obligation update gsk esg performance report march ceos statement pleased provide report esg performance gsks purpose unite science technology talent included performance strong progress get ahead disease together vaccine medicines access initiatives reaching million made building trust operating responsibly integral people lower income countries part strategy culture ultimately support returns progressed global health pipeline assets priority shareholders reduce risk help people thrive diseases including malaria tb deliver sustainable health impact scale rd projects relevant amr targeting pathogens esg focus six core areas access healthcare global deemed 'critical ' 'urgent ' us cdc health health security environment diversity equity phase iii trials started diversity plan enrol inclusion ethical standards product governance affected disease studied areas address matters business improvement gender ethnicity representation stakeholders greatest leadership positive impact societys urgent challenges reduction indirect carbon emissions latest available scope data sets progress making area delivery target reduce water use operations supplements annual report hope information level transparency helpful particularly investors employees completing mandatory training strengthen measurement reporting gsks overall esg performance year introduced new esg esg performance continues recognised ranked performance rating st access medicines index th consecutive time ranked nd sp global corporate sustainability new rating one corporate kpis measures assessment pharmaceutical industry maintained progress key metrics aligned six focus topquartile positions msci iss corporate rating areas included metrics developed sustainalytics esg ratings stakeholder input assessed aggregated single overall performance score pleased report proud progress keep approach esg gsks performance track details constant review responsible business found pages static requirement operating environment continues change pace continue adapt respond proactively change approach ensure gsk continues deliver strong esg performance alongside broader performance company emma walmsley chief executive officer gsk esg performance report march approach access global health environment dei ethical standards product governance appendix approach esg integral part strategy purpose impacts everything lab patient six esg focus areas esg governance deliver purpose build trust embed esg performance monitored regularly board esg everything identified six esg focus level corporate responsibility committee crc gsk areas address material business leadership team glt crc oversees progress issues matter stakeholders focus areas commitments including performance core strategy areas meeting expectations stakeholders greatest positive impact societys urgent glt senior management responsible delivery challenges focus areas six focus areas report regularly crc access healthcare progress see pages annual report global health health security esgaligned remuneration environment diversity equity inclusion dei remuneration committee support crc introduced esg performance measures ethical standards short longterm incentive plans reward delivery key product governance esg commitments esg element consists human capital approach guided extensive stakeholder engagement management form diversity equity inclusion key issues relevant industry company forms annual bonus opportunity glt results recent materiality assessment reaffirmed climate net zero nature net positive ambitions form material issues business well aligned longterm incentive plan opportunity senior leaders six esg focus areas aware however metrics align esg performance rating see annual responsible business static requirement operating report information environment continues change pace continue adapt respond proactively change approach ensure gsk continues deliver strong esg performance gskcom materiality assessment esg performance rating support integration esg strategy delivery assess performance make esg performance measurable verifiable glt accountable delivering progress metrics introduced new esg performance rating rating one regularly reviews performance along boards crc corporate kpis measures progress key metrics individual metric assessed either track metric met aligned six focus areas included exceeded track work least metric metrics summarised pages metrics achieved track metric missed developed stakeholder input understanding addition order calculate overall esg performance key issues industry company committed rating performance across metrics aggregated single ensuring esg performance rating responds score illustrate whether track track work stakeholder expectations continue review metrics track rating defined business external expectations change create esg performance rating management sought track metrics track metrics track work metrics either track track work well defined ensure standardised approach used consistently future years track metrics track ambitious achievable externally assured meaningful stakeholders gsk esg performance report march approach access global health environment dei ethical standards product governance appendix approach continued esg performance rating esg performance rating track based performance metrics met exceeded assessment performance annual targets reviewed overall esg performance rating score externally assured see esg focus areas six commitments metrics performance access make products available valuebased prices sustainable business implement access read strategies increase use medicines vaccines treat protect underserved people performance metrics highlights focus areas develop externally publish pricing published pricing access principles guide access principles approach responsible pricing progress towards goal reaching billion reached million people people lower income countries products products supplied additional million doses albendazole global health develop novel products technologies treat prevent priority diseases including pandemic threats health performance metrics highlights focus areas security progress three global health pipeline assets progressed global health pipeline assets address read address priority diseases priority diseases including malaria tuberculosis tb positive phase iia study results new firstinclass candidate medicine patients tb australian therapeutic goods administration approved use singledose tafenoquine children aged two combination chloroquine radical cure p vivax malaria fda approved triumeq pd increasing age appropriate treatment options children living hiv environment commit net zero nature positive healthier planet ambitious goals set read performance metrics highlights focus areas climate reduced scope carbon operational operational emissions reduction scope emissions marketbased emissions reduced scope value chain emissions industrialisation green ventolin initiated since clinical nonclinical data available support made good progress towards reformulating ventolin regulatory submissions could reduce climate impact metered percentage carbon offset volume project pipeline dose inhalers clinical trials successful water gsk sites suppliers compliant average percentage gsk sites wastewater discharge limits suppliers compliant wastewater active sites good water stewards line pharmaceutical ingredient limits percentage alliance water stewardships definition suppliers compliant amr industry alliance common antibiotic manufacturing achieved target reducing overall water framework discharge limits use baseline review target waste materials completed baseline biodiversity assessments operational waste material reduction sites sites biodiversity highrisk materials implementing sustainable number highrisk materials implementing sourcing roadmaps sustainable sourcing roadmaps million figure includes people reached synflorix rotarix cervarix opv mosquirix vaccines people access generic dolutegravir product voluntary licensing agreements however include people reached albendazole assessment made gsk cope emissions cover emissions direct combustion fuels sites generate heat electricity emissions sales fleet vehicles fugitive losses propellant manufacturing inhalers losses refrigerants used gskowned ancillary equipment emissions onsite waste treatment scope emissions include purchased electricity steam compressed air chilled water percentage mtco offsetting volume project pipeline gsk esg performance report march approach access global health environment dei ethical standards product governance appendix approach continued esg focus areas commitments metrics performance diversity equity create diverse equitable inclusive workplace enhance recruitment diverse patient populations inclusion clinical trials support diverse communities read performance metrics highlights focus areas phase iii trials initiated phase iii trials initiated proactive proactive plans place designed enrol demographic plans place appropriately diverse trial participants consistent women made vpandabove roles globally disease epidemiology compared performance towards aspirations fair us ethnically diverse leaders vp equitable opportunities level increased percentage black women hold least vpandabove african american hispanic latinx vpand roles globally end leaders least ethnically diverse leaders uk ethnically diverse leaders roles vp us increase roles vp however percentage percentage black african american black vpandabove leaders remained hispanic latinx vpandabove leaders year year significantly exceeded target increase spend least ethnically diverse leaders certified usbased diverseowned suppliers roles vp uk increase percentage black vpandabove leaders year year improve yearonyear spend certified usbased diverseowned suppliers ethical promote ethical behaviour across business supporting employees right thing working standards suppliers share standards operate responsible way read performance metrics highlights focus areas employees complementary workers achieved overall completion gsk 's mandatory complete gsks mandatory training training employees completed percentage employees believe training met completion rate speak things dont feel right complementary workers general industry benchmark employees believe speak number employees leaving gsks employment things n't feel right misconduct last months versus number employees leaving gsk 's employment threeyear rolling average misconduct increased result enhancing direct highrisk suppliers achieve gsks risk identification targeted interventions minimum ecovadis score improvement direct highrisk suppliers achieved minimum plan place ecovadis score product commit maintaining robust quality safety processes using data new technologies responsibly governance performance metrics highlights focus areas read average number critical major findings received warning letters us fda critical fdamhraema regulators findings mhra ema regulators percentage inspections regulators inspections regulators critical critical findings official action indicated findings official action indicated number fda warning letters continued reduce level recalls across total number class iii external product recalls markets class product recalls across markets fewer class ii iii recalls register disclose human subject research made protocol summaries gsk products specifically register protocol summaries results available listed studies summaries studies initiated disclose data sharing since setup gsk trial results summaries studies results due register general industry benchmark according research kornferry n continued embed greater focus use risk analytics monitoring aligned increasing levels business activities enhancing risk identification targeted interventions additionally focused closure cases resulting decrease open cases year end compared prior years correlation rising numbers employees dismissed agreed leave company voluntarily result misconduct gsk esg performance report march approach access global health environment dei ethical standards product governance appendix approach continued putting people heart success culture focusing diversity equity inclusion committed making gsk place people continuing focus building diverse thrive culture ambitious patients organisation equitable inclusive culture accountable impact right thing means everyone feels welcome valued included delivering support people things better faster focusing leadership representation aspirations implemented matters means setting clear objectives annual dei training invested development tools accountability results giving everyone support build inclusive leaders support awardwinning space need succeed means everything leadership development programme 'accelerating difference ' responsibly care integrity people patients support women ethnically diverse leaders also around world count us continued evolve people policies processes practices support recruitment retention development dedicated significant leadership energy diverse workforce details aspirational targets dei bringing life ahead together purpose strategy culture people business suppliers found across gsk also placed real emphasis individual ownership culture small changes need driving performance choice make reality change supported team conversation guides simple tools used globally support performance choice approach hybrid working better faster decision making greater clarity officebased roles quarter people accountabilities ambitious focused objectives continues allow us find right balance onsite remote working framework balanced driving collective june introduced code sets culture individual performance well supporting individual well commitments gsk people make flexibility supporting personal wellbeing driving performance deliver ambition right way gsk people sign making us attractive employer code annually personally commit im year clear expectations gskcom code spend enough time together person help us continue build sense community connectedness enable development making gsk place people thrive better achieve ahead together ambition core ahead together ambition make gsk place people thrive although people thrive individual developing outstanding people also believe common themes matter committed developing outstanding people giving firstly belief purpose desire live culture people opportunities grow gsk people expected contribute delivering ambition secondly feeling included agreed development plan regardless grade role able opportunities keep growing underpinned robust conversation understand support feedback space needed succeed finally space support needed succeed continue feeling good positive mental physical financial social invest development initiatives training wellbeing requires gsk place people feel accessed keep growing campus central welcome valued environment including policies platform training knowledge sharing workplaces ways working wholeheartedly enables supports person deliver best also redesigned talent framework focusing reviews people performance living culture supporting people managers future potential gives us simpler assessment process people managers play crucial role helping teams line culture support placing best people thrive bring culture life expect people managers critical roles strong diverse succession plans motivate focus care develop teams last allows us spend time development action two years delivered first line leader training anchored planning less process four areas population addition launched new senior leader programme 'leading leaders ' build leadership development senior levels organisation preparation brought people managers together virtual event bring life biggest priorities support managers setting focused ambitious objectives teams aligned innovation performance trust culture priorities gsk esg performance report march approach access global health environment dei ethical standards product governance appendix approach continued health wellbeing improvements recognising rewarding people announced improvements health wellbeing sharing success recognising rewarding people benefits better support people different life stages progress made made make sure offerings fair inclusive continues important part culture addition include new global minimum standard weeks parental bonus scheme rewards performance across company leave primary secondary carers forms family year award population extra ahead new global minimum standard care family member together awards delivering exceptional performance end life serious health emergencies insured benefits line culture people identified missed include sex partners wherever possible new financial performance deliver objectives wellbeing service mental health training available live culture year addition annual bonus everyone longterm incentive structure also gave special thank people excluding glt allowing us recognise real november gave onetime discretionary payment time achieved together preparation separation people feeling greatest impact rising costof unprecedented transformation gsk everyone living challenges payment given almost half received oneoff weeks salary march separate global workforce countries using consistent criteria bonus payout determine eligible countries remain energised continually live evolve culture understanding people experience gsk line internal external environment part regularly measure people experience gsk including everyones objectives starting top leadership team progress culture focus areas place work members ambitious goals embed grow culture includes annual survey employees featuring questions shows act every day engagement confidence inclusivity culture focus areas trust priorities also run series pulse surveys year statistically significant population get timely insights culture progress well hot topics moment last year progress demonstrated increased engagement confidence delivery ambitions positive trends ambitions patients accountability impact right thing measures inclusion measure effectiveness global manager population teams provide feedback via annual one survey managers receive anonymised aggregate feedback effectiveness motivating team focusing people matters leading care inclusive leadership supporting performance development managers rated highly effective reports gsk esg performance report march approach access global health environment dei ethical standards product governance appendix access ambition positively impact health billion people end achieve developing vaccines medicines making available responsible pricing strategic access programmes partnerships bn people reached lower countries covered viiv vaccines supplied lowest income countries healthcares paediatric prices gavi vaccine products voluntary licensing agreements alliance since generic manufacturers commitment assess performance make products available valuebased prices develop externally publish pricing access principles sustainable business implement access strategies progress towards goal reaching billion people increase use medicines vaccines treat lower income countries products protect underserved people aim make vaccines medicines available discovery development medicines vaccines responsible prices accessible patients sustainable complex takes significant time risk investment business making sure underserved people succeed follow set pricing access principles published treated protected access strategies first time help us get balance right recognition action taking get ahead disease responsible pricing sustainable profitable business together ranked first access medicines index allows us reinvest financial returns future innovation eighth consecutive time ensuring people access medicines vaccines gskcom position pricing access pricing access principles putting right value innovation pursue areas unmet medical need deploying cuttingedge also recognise health inequities including higher income science advanced technology develop effective countries help uninsured underinsured patients navigate medicines vaccines speed scale precision healthcare systems programmes increase access provide financial disease management support example compare offer already available patients us gsk viiv healthcares patient generate evidence clinical trials realworld assistance programs foundation provided prescribed settings establish added value medicines medicines vaccines lowincome vaccines principles ensure set prices across uninsured underinsured medicare part patients portfolio line benefit bring patients health systems measured clinical economic social outcomes us year combined average net price discounts rebates allowances pharmaceutical take consideration socioeconomic status country vaccines portfolio increased average list ensure affordability availability products including price increased compared list industry using tiered pricing based world bank income classification demonstrates responsible pricing decisions vaccine tenders collaborate global health partners past five years average net price products increase impact lower income countries example decreased annually average list price rose supplying vaccine doses lowest prices gavi compared list industry operate international alliance improve access vaccines countries robust pricing approvals developing access plans lowest gdp viiv healthcare provides nonprofit pricing informed payers also work create stability public health systems lowincome least developed predictability payers business engaging proactively subsaharan african countries antiretroviral medicines upcoming product launches plan budgets treat people living hiv well innovation prevent adjusting prices account inflation hiv transmission million figure includes people reached synflorix rotarix cervarix opv mosquirix vaccines people access generic dolutegravir product voluntary licensing agreements however include people reached albendazole assessment made gsk ndustry averages sourced drug channels annual brandname drug list change report gsk esg performance report march approach access global health environment dei ethical standards product governance appendix access continued reaching patients lower income countries ambitious patients develop access strategies hiv make real difference nearly two billion people supporting production generic drugs also improve globally lack access essential medicines vaccines access viiv healthcare medicines patent pool could prevent treat diseases relieve suffering improve quality mpp signed new voluntary licensing agreement allow life prevent deaths goal reach billion people generic manufacturers develop manufacture supply lower income countries products end cabotegravir longacting hiv preexposure prophylaxis access initiatives voluntary licensing donations aims enable access drug least developed lowincome work gavi vaccine alliance reached lower middleincome subsaharan african countries million people products supplied additional coming years meantime viiv working stakeholders million doses albendazole including global health agencies nongovernmental decades worked partners strengthen organisations ngos governments community partners healthcare systems key increasing access medicines plan support successful introduction cabotegravir lower income countries partner others longacting preexposure prophylaxis national right capability geographic reach local knowledge get programmes viiv manufactured product innovation patients medicines lowincome countries viiv healthcare also voluntary licensing agreements file patents medicines enforce historic patents generic manufacturers produce sell lowcost single lets companies manufacture supply generic fixeddose combination products containing hiv medicine versions gsk medicines countries dolutegravir adults low middleincome countries one direct licence others via mpp vaccines similar agreements generic manufacturers children never important work organisations like covering countries result voluntary licence gavi vaccine alliance help us reach agreements around million people living hiv across vulnerable people pressure placed healthcare systems countries access generic product containing dolutegravir lower income countries covid pandemic resulted end least people living hiv reduction routine immunisations putting millions childrens antiretrovirals low middleincome countries health risk viiv healthcare donated around packs partner gavi since foundation antiretroviral medicines ngo partners national hiv reserve lowest vaccine prices gavi similar aids programmes support people living hiv organisations passed milestone supplying impacted conflict ukraine viiv also provided gavi one billion vaccines since positive action programme support communitybased organisations humanitarian response partnership includes supplying cervarix critical vaccine activities within ukraine surrounding countries lower income countries addressing cervical cancer hosting refugees supplied around million doses pneumococcal vaccine synflorix eight gavieligible countries lowest positive action viiv healthcare 's community grantgiving price rotarix vaccine rotavirus reaches children programme celebrated th anniversary across gavieligible countries four former gavi countries yearlong campaign showcase people heart since march well synflorix also offered programme partners implementation rotarix humanitarian mechanism civil society progress made collaboration invested organisations serving refugees working emergency million reaching approximately people situations also longstanding supplier oral polio providing grants across countries vaccines opv unicef alone supplied around million doses help eradicate polio malaria working partners million children africa neglected tropical diseases received least one dose malaria vaccine since donated billion albendazole tablets mosquirix rtssas e developed years including million supports efforts gsk partners mosquirix first vaccine end lymphatic filariasis commonly known elephantiasis clinical trials shown acceptable safety profile reduce morbidity intestinal worms soiltransmitted feasible deliver substantially reduce deadly severe malaria helminths schoolage children also extended children september awarded pre soiltransmitted helminths commitment include preschool qualification vaccine following rigorous regulatory children made additional commitment donate process ensure meets standards quality safety albendazole treatment echinococcosis according efficacy suitable target population latest data benefited million prerequisite un agencies procure vaccine people since programme began million people important step rolling countries moderate high treated lymphatic filariasis programme p falciparum malaria transmission countries including million children gsk esg performance report march approach access global health environment dei ethical standards product governance appendix access continued gsk path bharat biotech agreed product transfer whocoordinated malaria vaccine implementation help ensure longterm supply rtss malaria vaccine programme mvip ghana kenya malawi june committed supply million doses next gsk also committed supply million doses three years addition donation million doses adjuvant rtss malaria vaccine strengthening healthcare systems longstanding partnership amref health africa partnership save children aims cut number continues tuberculosis tb malaria programme children dying preventable treatable diseases ethiopia kenya launched improve education strengthen healthcare systems drive rd address critical diagnosis treatment underserved communities knowledge gaps create systemic change childrens health complemented specific paediatric hiv testing component global level support save childrens emergency towards end funded viiv healthcares positive preparedness response capabilities investing data action programme worked healthcare workers analytics early action protocols since partnership managers strengthen healthcare systems improve reached million children globally across countries laboratory testing diagnostics surveillance information trained healthcare workers supported systems supply chains community healthcare workers tb malaria programme healthcare gsksave children partnership began work workers trained across countries two uns green climate fund projects malawi kenyan subcounties supported programme senegal support national governments healthcare workers able effectively diagnose objectives addressing health impacts climate change manage tb malaria uptake contributing resilient healthcare systems preventative services community ethiopia integrating collaboration bill melinda gates ceo tb malaria hiv care means women children roundtable programme also working jj novartis eli benefit screening three diseases single lilly pfizer train healthcare workers six african countries antenatal care appointment programme trained around healthcare workers brought together amref health africa cognizant one gsks technology partners integrate three digital tools better plan identify respond healthcare worker training needs community level platform successfully piloted hope reach thousands healthcare workers across subsaharan africa quality training help meet needs millions people community investment cash product inkind time management costs total community investment value gsk medicine vaccines provided us patient assistance programs foundation pr metric contributes esg performance rating metrics data externally assured product donations valued global average cost goods reported yearend results employee volunteering significantly impacted covid pandemic product donation included within total community investment figures reported gsk esg performance report march approach access global health environment dei ethical standards product governance appendix access continued us pricing year change list net price change combined average net price pharmaceutical vaccines portfolio us since previous year change average list price us since previous year year list net price compound annual growth rate change net price discounts rebates allowances products us past years change average list price us past years product reach doses supplied lower income countries doses synflorix vaccines supplied gavi pr doses rotarix vaccines supplied gavi pr doses cervarix vaccines supplied gavi pr doses opv vaccines supplied unicef pr doses mosquirix rtssas e vaccines supplied mvip pr albendazole tablets donated help eliminate lymphatic filariasis pr albendazole tablets donated help treat intestinal worms pr total doses supplied pr product reach people reached lower income countries people access generic dolutegravir product voluntary licensing agreements ' estimated children reached synflorix gavi ' estimated children reached rotarix gavi ' estimated girls reached cervarix gavi ' estimated people reached opv unicef ' estimated people reached mosquirix rtssas e mvip ' total people reached ' people reached healthcare access programmes people accessing healthcare service worker educational session work save children ' people accessing healthcare worker service facility result bill melinda gates ceo roundtable programme ' people reached viiv healthcares positive action children fund grants ' people reached viiv healthcares positive action strategy grants ' people reached us patient assistance programs ' pr metric contributes esg performance rating metrics data externally assured calculated across gsk viiv healthcare products product donation included within total community investment figures reported product donations valued global average cost goods reported yearend results chronic ongoing treatment cumulative number people access dolutegravir rather annual data reported figure estimated based sales generic dolutegravirbased products voluntary licensing agreements updated methodology include sales generic dolutegravirbased products previous years sales tld tenofovir disoproxil lamivudine dolutegravir included formed large majority generic sales worldwide time around total lower figure reported esg performance report overestimated due stock building pandemic w e three healthcare access programmes ended people accessing malaria comic relief partnership healthcare workers trained partners people accessing healthcare worker service facility result healthcare workers training programmes ur total lower previous years due partnership programmes concluding bill melinda gates ceo roundtable programme funded five pharmaceutical companies gsk jj novartis lilly pfizer bill melinda gates foundation funder organisation equal contributor reach number total programme reach divided six r data collected provided grantees data capture month cycle grantees report every six months previous six months therefore final data available june report updated reflect actual figure gsk esg performance report march approach access global health environment dei ethical standards product governance appendix global health health security use expertise address biggest health challenges underserved people around world bn investment rd help global health pipeline assets rd projects relevant us get ahead infectious address priority antimicrobial resistance diseases lower income diseases progressed pipeline countries commitment assess performance develop novel products technologies treat progress three global health pipeline assets address prevent priority diseases including pandemic threats priority diseases unique important role play improving health two worldleading dedicated global health innovation patients around world helping world prepare hubs vaccines medicines developing products future health security challenges determined help technologies prevent treat priority infectious diseases change trajectory high burden infectious diseases progressed global health pipeline assets disproportionately affect underserved people around world address priority diseases exceeding target three trapping cycles disease poverty wellfunctioning healthcare systems critical enabling deliver goals dedicated global health unit access right treatments vaccines work success measured health impact profit including longterm partners help strengthen healthcare systems lower viiv healthcare working potential vaccines income countries driven local needs work increase medicines targeting high burden infectious diseases underserved peoples access medicines vaccines putting unique rd scientific expertise work address described access worlds biggest health challenges including tuberculosis tb malaria antimicrobial resistance amr global health rd billion accelerate rd want discover shorter simpler safer treatments tb alongside partners publicprivate june gsk including viiv healthcare announced research consortiums continued progress pipeline billion investment rd help us get ahead infectious novel tb medicines announced positive phase iia diseases lower income countries year investment study results gsk new firstinclass candidate support rd new medicines vaccines prevent medicine patients tb results study demonstrated treat tb malaria hiv enteric diseases neglected tropical potential candidate become component diseases reduce amr simpler treatment regimens future partnership help fund goal ending hiv aids developing bioversys university lille innovative medicines enabling access innovative treatment prevention initiative imi project trictb also successfully completed options advancing industryleading pipeline vaccines phase trials bvlgsk potential help including firstinclass vaccines invasive nontyphoidal tackle drug resistance boosting activity existing salmonellosis shigellosis rd investment aims reduce antibiotic threat amr gsk industry leader two publicprivate research consortiums supported imis amr accelerator eratb tackling tuberculosis unitetb aiming accelerate rd new tb tb responsible million deaths making drugs treatment regimens drugresistant drug worlds secondleading cause death infectious disease sensitive tb covid gsk esg performance report march approach access global health environment dei ethical standards product governance appendix global health health security continued consortium aims enable progression bettertolerated fda also approved triumeq pd first dispersible single drug regimens shorter duration tb patients worldwide tablet formulation containing dolutegravir children weighing goal improving quality life life expectancy kg increases ageappropriate treatment projects bring together expertise public sector industry options children living hiv end academic partners significantly reduce development time committee medicinal products human use chmp preclinical candidates pharmaceutical companies ema also issued positive opinion recommending marketing authorisation triumeq pd children kg tb candidate vaccine mase demonstrated potential reduce active tb pulmonary disease among adults addressing enteric diseases neglected latent tb infection phase llb trial sub licensed bill melinda gates medical research institute tropical diseases continue development first major step tb two global health rd centres researching prevention almost years partnership exemplifies potential solutions enteric diseases neglected tropical gsks approach global health rd unique contribution diseases scientists looking range diseases across scientific expertise focus research early invasive nontyphoidal salmonella typhoid paratyphoid fever development partnering worldleading organisations group streptococcus visceral leishmaniasis chagas disease funders late development manufacturing access lymphatic filariasis soiltransmitted parasites dengue fever vaccine reach patients scale invasive nontyphoidal salmonella lifethreatening children africa key driver amr using protecting children malaria innovative vaccine technology partnership university malaria complex disease caused plasmodium parasites oxford vaccints develop potential candidate vaccine five different types plasmodium parasites known using generalised modules membrane antigens technology infect humans p falciparum prevalent subsaharan involves manipulating bacteria cells produce vaccines africa p vivax common south southeast asia manufactured scale costeffectively lowincome latin america know one tool enough get countries ahead malaria particularly due growing resistance continue invest next generation transformative tools supporting scientific research capacity africa partners weve brought two products prevention help support global rd december announced treatment malaria market worlds first vaccine fourth call proposals part africa open lab call malaria see access singledose radical proposals aimed african earlycareer scientists based cure p vivax malaria subsaharan africa focus infectious diseases disproportionately affect subsaharan populations march australian regulator therapeutic goods malaria tb neglected tropical diseases ambition administration approved use singledose medicine support african earlycareer scientists accelerate progress tafenoquine children aged two combination getting ahead major global health challenge help chloroquine radical cure p vivax malaria treatment develop next generation african scientific leaders targets liver stage disease prevent relapse follows africa ncd open lab first singledose radical cure developed gsk funded research projects focused noncommunicable partners medicines malaria venture developed dispersible diseases tablet formulation make easier children take hiv collaboration action almost million people living hiv globally live low middleincome countries end generic dolutegravir dispersible tablet mg formulations specially developed children living hiv rolled countries two years first generic formulation received tentative us fda approval us presidents emergency plan aids relief scheme facilitated innovative publicprivate partnership viiv clinton health access initiative unitaid two generic manufacturers sublicences medicines patent pool providing technology transfer knowhow well regulatory planning support second publicprivate partnership also ongoing accelerate generic development introduction generic dolutegravirabacavirlamivudine dispersible tablet formulations gsk esg performance report march approach access global health environment dei ethical standards product governance appendix global health health security continued strengthening health security many factors jeopardise health security provides clear guidance manufacturers global new emerging infectious diseases rise amr antibiotic supply chain help ensure antibiotics climate change nature loss also pose significant risk made responsibly compliance scientifically robust discharge limits using scientific knowhow collaborating others help world better prepare future health challenges gskcom position antimicrobial resistance getting ahead antimicrobial resistance future pandemic preparedness amr poses urgent threat public health study published help preempt respond next pandemic lancet analysing data working governments stakeholders strengthen countries territories showed million deaths global preparedness means drawing directly attributable bacterial amr greater toll learned covid previous outbreaks championing hiv malaria getting ahead infectious disease innovation promoting sustainable approaches impending threats like amr help protect lives livelihoods biopharmaceutical sector public health healthcare systems july gsk along major biopharmaceutical rd expertise partnering amrfocused companies signed berlin declaration sets organisations carbx driving innovation industrys vision equitable access future pandemics prevention treatment rd projects declaration stated sectors willingness reserve across medicines vaccines relevant amr ranging allocation realtime production medicines vaccines early latestage development include gepotidacin distribution priority populations determined health could first novel oral antibiotic treatment authorities future pandemics dependent factors uncomplicated urinary tract infections years strong healthcare systems recipient countries announced exclusive licence agreement spero committed using worldclass global vaccine therapeutics tebipenem hbr latestage antibiotic may manufacturing network support pandemic preparedness treat complicated urinary tract infections projects response gsk concluded series contracts target pathogens deemed critical urgent would provide least million doses pandemic us centers disease control prevention see influenza vaccine governments around world february annual report rd pipeline extended pandemic influenza vaccine stockpile surveillance central tackling amr shared data contract united states government followed longrunning survey antibiotic resistance soar renewed agreement june supply pandemic study tracks communityacquired respiratory infections influenza vaccines july contract new amr register developed vivli continue government canada seasonal pandemic share new data available initiative help build influenza vaccines signed agreement europe collective understanding pathogens evolving reservation future production supply pandemic needed protect influenza vaccines also continuing partner biomedical advanced research development authority also promote effective stewardship antibiotics barda manufacture assess safety enable access continue train healthcare immunogenicity pandemic influenza vaccine candidates professionals around world using prescribing antibiotics appropriately importance surveillance gskcom position pandemic preparedness studies support responsible manufacturing antibiotics work amr industry alliance set global limits wastewater antibiotic discharges factories see environment also worked alliance publish new antibiotic manufacturing standard global health pipeline assets priority diseases number assets progressed global health pipeline address priority diseases pr pr metric contributes esg performance rating metrics data externally assured gsk esg performance report march approach access global health environment dei ethical standards product governance appendix environment continue work hard protect environment often partnership others weve set clear measurable targets help achieve goals reduction scope gsk sites completed gsk sites suppliers carbon emissions compared baseline biodiversity compliant wastewater assessments discharge limits commitment commit net zero nature positive healthier planet water ambitious goals set average percentage gsk sites suppliers compliant wastewater active pharmaceutical ingredient assess performance limits percentage suppliers compliant climate amr industry alliance common antibiotic manufacturing operational emissions reduction scope marketbased framework discharge limits emissions waste materials industrialisation green ventolin initiated clinical operational waste material reduction sites nonclinical data available support regulatory submissions biodiversity percentage carbon offset volume project pipeline number highrisk materials implementing sustainable sourcing roadmaps recognise worlds climate nature crises pose achieving goals support longterm value creation build urgent threat human health worsening impact diseases trust stakeholders reduce risk operations putting healthcare systems pressure committed require us collaborate patients suppliers work towards net zero nature positive healthier planet regulators peers integrating sustainability ambitious goals set goals cover operations ensure delivery entire value chain drug discovery disposal g skcom position environmental sustainability environmental products well investing protecting restoring nature action report time investing get ahead health impacts climate change developing manufacturing new medicines vaccines diseases affected climate change well working partners improve healthcare system resilience climate change climate set clear pathway net zero impact climate comply standard change required ambitious goals planned carbon reduction pathway reductions offsets addition set longerterm target gsk set carbon ambition net zero impact reduce carbon emissions least climate plan meet goal aims remainder tackled highquality offsets carbon reductions across scopes baseline remaining offset investment highquality sbti accredited carbon target set prior naturebased solutions demerger aligned oc pathway reduction pathway significantly ambitious sbti science based targets initiative sbti published netzero standard minimum requirement halve emissions new carbon netzero standard aim addressing stakeholder concerns around inconsistent methodology definitions net zero currently seeking reaccreditation sbti targets fullyfocused biopharma company also submitted target verification sbti netzero standard gsk esg performance report march approach access global health environment dei ethical standards product governance appendix environment continued supply chain emissions value chain carbon footprint made approximately total emissions footprint comes goods services buy september scope emissions operations launched sustainable procurement programme scope emissions suppliers requires suppliers take action carbon power heat scope emissions people using products transport water waste sustainable deforestationfree mostly metereddose inhalers sourcing materials among things scope emissions required disclose emissions set carbon reduction targets aligned oc switch renewable power heat targets part new programme actively support suppliers reduction carbon emissions investment nature education adoption new environmental based solutions remaining footprint sustainability measures october gsk supplier scopes forum attended top suppliers presented renewable electricity scope sustainability plans along clear expectations available net zero emissions across full value chain support suppliers scopes continued build capability across procurement function g skcom net zero pathway integrate sustainability including tender questions contractual provisions performance metrics managing operational footprint supply chain emissions shared challenge across reduced scope carbon emissions industry sector collaborating find shared solutions compared primarily increasing example participate manufacture initiative use renewable electricity continued delivery energy industry peers encourages suppliers efficiency across sites installation new solar measure manage reduce emissions suppliers panels upgraded lighting replacing chillers reduce registered platform account almost threequarters use ozonedepleting refrigerant example site emissions purchased goods manufacture irvine scotland closedloop heating system helped drive codeveloped activate programme along four reductions operating costs onsite renewables biogas founding companies help active pharmaceutical ingredients provide energy end api suppliers gain access green funding practical member committed source support accelerate decarbonisation initiatives renewable electricity reached also working peers energize increase since since programme encourage use renewable energy throughout also member ev committed install pharmaceutical sectors supply chain nine suppliers charging infrastructure sites transition sales fleet formed first energize buyers cohort together purchase lowcarbon vehicles october hybrid two terawatthours renewable electricity fully electric vehicles made fleet part sustainable markets initiative health systems chargers installed sites number chargers task force made ceos seven global healthcare increasing locations companies task force announced joint action nearterm emissions reduction targets accelerating reducing value chain emissions delivery net zero healthcare systems addressing emissions following demerger consumer healthcare business across supply chains patient care pathways clinical trials restating value chain carbon footprint baseline year latest available data scope emissions use products emissions reduced compared reductions use medicines vaccines patients makes reflect evolution product portfolio total climate impact predominantly propellant used metered dose inhalers asthma chronic obstructive pulmonary disease investing rd programme reduce greenhouse gas emissions vital medicine made good progress towards reformulation ventolin could reduce climate impact clinical trials successful climaterelated financial disclosures see pages annual report disclosure climate risk resilience line task force climate related financial disclosures tcfd framework argets measured baseline previously stated net zero new longerterm target aligned sbti netzero standard definition net zero gsk esg performance report march approach access global health environment dei ethical standards product governance appendix environment continued nature committed working towards goal net materials circular economy positive impact nature reducing environmental targets impacts across water waste materials biodiversity zero operational waste including eliminating singleuse investing protecting restoring nature plastics protecting nature plays vital role protecting human health environmental impact reduction products habitat degradation increases risk new human pathogens packaging pandemics emerging natural world also provides waste reduction supply chain ingredients existing medicines inspiration new ones continued reduce waste sites making good progress meeting water waste increase amount materials recovered circular materials biodiversity targets one first routes like reuse recycling example sites companies trial science based targets network nature introduced recycling chemical containers sbtn methodology better understand impacts new solvent recovery processes eliminated use dependencies nature also member taskforce disposable gowns naturerelated financial disclosures tnfd also targeting materials across existing product developing risk management financial disclosure portfolio includes removing paper leaflets moving framework similar tcfd eleaflets regulation permits vaccines business water also stopped using pvc blisters packing prefilled syringes removing plastic film wrapping used pallets targets built capability perform ecodesign analyses achieve good water stewardship sites completed detailed analysis antibiotic product reduce overall water use operations identified number projects reduce environmental water neutral operations key suppliers impact rd laboratories upper providence waterstressed regions certified green labs considered gold zero impact api levels sites key suppliers standard laboratory sustainability best practice around world reduced overall water use operations g skcom materials waste since sites high water stress regions decrease overall water use sites high biodiversity water stress regions baseline achieved overall water use reduction target review targets sites good water stewards line positive impact biodiversity sites alliance water stewardships definition agricultural forestry marinederived materials initially identified three water basins waterstressed sustainably sourced deforestation free areas algeria india pakistan manufacturing progressing plans net positive biodiversity sites aim water neutral manufacturing sites investing individual site action plans improve facility nashik india built plants rainwater harvesting habitats protect species improve soil water quality completed baseline biodiversity assessments committed keeping api emissions sites commenced biodiversity uplift projects manufacturing including might contribute three largest rd facilities also completed full antimicrobial resistance amr levels might assessment biodiversity impact across entire value negative impact human health environment chain line latest sbtn guidance taking applies sites key suppliers targeted actions address highlystressed areas sites suppliers new sustainable sourcing standard outlines manufacture antibiotics complied amr alliance industry environmental social ethical requirements must standards safe discharges met supply chain considered sustainably partner prioritisation risk evaluation sourced first stage addressing critical medicines environment premier project agricultural forestry marinederived materials reached innovative medicines initiative collaboration across industry target sustainably sourced paper palm academia regulators involves working stakeholders oil roadmaps place achieve develop tools models data characterise environmental risk engaged associated suppliers map full apis making environmental data apis accessible supply chains involved understand existing sustainability exploring feasibility greener drug design standards identify gaps establish remediation plans g skcom water value chain water footprint position pharmaceuticals environment argets measured baseline see environment basis reporting definition z ero impact predicted effect concentrations gsk esg performance report march approach access global health environment dei ethical standards product governance appendix environment continued also building resilience supply invested community reforestation project ghana materials scoping initiatives help either reduce creates jobs promotes gender equality supports use packaging redesign portfolio consolidation provision clean water sanitation project follows types efficiencies avoid altogether forestry stewardship council principles generated carbon transitioning synthetic alternatives appropriate credits line verified carbon standards criteria environmental integrity retired support leadup un convention biological diversity carbon neutrality claim inhaler product uk critical cop conference canada end also invested project indonesia aims restore worked partners call mandatory disclosure hectares mangroves communityled projects businesses financial institutions impacts project aims deliver tonnes dependencies nature also worked partners help removal credits annually covering raise business ambition nature ensure health approximately forecasted residual emissions healthcare sector part dialogue based current carbon reduction glidepaths g skcom biodiversity collaboration key ensuring adequate supply highquality protecting restoring nature projects meet rigorous standards part leaf coalition lowering emissions accelerating forest finance investing nature protection restoration fundamental privatepublic effort protect tropical forests also achieving climate nature goals well positive impacts testing guidance voluntary carbon market integrity human health initiative working establish globallystandardised aim maximise reductions make benchmark guide use carbon credits companies environmental impacts offset emissions abated robust criteria carbon offsetting naturerelated financial disclosures prioritise credits highquality technically robust accredited see pages annual report plan projects contribute land protection restoration disclose impacts dependencies nature line potential deliver nature social health cobenefits emerging tnfd framework local communities adaptation resilience climate change nature loss altering burden also working research develop new medicines spread disease globally exacerbating existing health threats vaccines climateaggravated diseases creating new ones putting healthcare systems pressure funding allocated date year billion rd increasing health inequalities means health particularly investment infectious diseases disproportionately impact within vulnerable communities must key part adaptation lower income countries focused climateaggravated diseases resilience discussions see global health joined race resilience campaign pledge help million people become resilient health impacts climate change gsk first biopharma company join campaign support investment partnerships organisations save children microsoft gsk working support local health interventions disease surveillance part commitment gsk also focus nature resilience naturebased action supporting people water stress part water resilience coalition reducing air pollution via alliance clean air argets measured baseline w regulatory obligations allow excluding plastics critical product discovery development health safety gsk esg performance report march approach access global health environment dei ethical standards product governance appendix environment continued energy natural gas purchased gwh electricity used gwh purchased renewable electricity gwh purchased nonrenewable electricity gwh onsite renewably generated electricity gwh exported electricity gwh coal gwh fossil fuels gwh renewable heat gwh purchased heating cooling gwh total energy operations gwh renewable electricity carbon scope emissions onsite fuel use thousands tonnes coe sales force vehicles thousands tonnes coe propellant emissions manufacture inhalers thousands tonnes coe onsite waste wastewater treatment thousands tonnes coe refrigerant gas losses thousands tonnes coe total scope emissions thousands tonnes coe electricity marketbased emissions thousands tonnes coe purchased heating cooling thousands tonnes coe total scope marketbased emissions thousands tonnes coe total scope locationbased emissions thousands tonnes coe total scope marketbased emissions thousands tonnes coe pr fermentationbiogenic releases thousands tonnes coe carbon scope emissions purchased goods services thousands tonnes coe capital goods thousands tonnes coe fuel energyrelated activities thousands tonnes coe transportation distribution upstream thousands tonnes coe waste generated operations thousands tonnes coe business travel thousands tonnes coe employee commuting thousands tonnes coe leased assets upstream thousands tonnes coe transportation distribution downstream thousands tonnes coe processing sold products thousands tonnes coe pr metric contributes esg performance rating metrics data externally assured cope emissions data assured metric tonne base data available gskcom ther propellant emissions data collected internal systems scope emissions reported unable split previous consumer healthcare business data accurate picture scope emissions later year gsk esg performance report march approach access global health environment dei ethical standards product governance appendix environment continued use sold products thousands tonnes coe emissions use propellantbased inhalers patients thousands tonnes coe end life thousands tonnes coe leased assets downstream thousands tonnes coe franchises thousands tonnes coe investments thousands tonnes coe total scope emissions thousands tonnes coe ozonedepleting substances odp inventory cfc hcfc equipment kg cfce odp calculated releases cfce kg cfce water use municipal million ground water million tankers million total water use million recycled sources million water use high water risk sites million water discharge wastewater municipal sewers million wastewater surface water million wastewater land million wastewater million total wastewater discharged million gsk sites supplier locations used gsk compliant amr alliance pr wastewater api limits pr metric contributes esg performance rating metrics data externally assured ther propellant emissions data collected internal systems scope emissions reported unable split previous consumer healthcare business data accurate picture scope emissions later year w ater use data assured base data available gskcom gsk esg performance report march approach access global health environment dei ethical standards product governance appendix environment continued waste materials total waste recovered via circular route thousand tonnes total waste disposed via noncircular route thousand tonnes total waste materials generated thousand tonnes pr circular waste total hazardous waste recovered via circular route thousand tonnes total hazardous waste disposed via noncircular route thousand tonnes total hazardous waste thousand tonnes total nonhazardous waste recovered via circular route thousand tonnes total nonhazardous waste disposed via noncircular route thousand tonnes total nonhazardous waste thousand tonnes total hazardous waste incinerated thousand tonnes total nonhazardous waste incinerated thousand tonnes total waste incinerated thousand tonnes total hazardous waste landfill thousand tonnes total nonhazardous waste landfill thousand tonnes total waste landfill thousand tonnes sustainable sourcing number highrisk materials implementing sustainable sourcing roadmaps pr compliance remediation environmental fines remediation spend pr metric contributes esg performance rating metrics data externally assured data recorded breakdown data unable report certain metrics years waste metrics originally part selected information subject independent assurance deloitte reported deloitte 'other matters ' section independent assurance report pages course assurance engagement deloitte unable obtain evidence needed support conclusion due complexity waste data significant remediation required measurement reporting waste metrics gsk took additional support third party complete remediation addition requesting deloitte remove waste metrics scope assurance engagement data includes previous consumer healthcare business gsk esg performance report march approach access global health environment dei ethical standards product governance appendix diversity equity inclusion want ensure people thrive foster diversity clinical trials support diverse communities becoming inclusive business central purpose vpandabove roles held ethnically diverse leaders vp phase iii trials include women globally level us demographic plan commitment create diverse equitable inclusive workplace enhance least ethnically diverse leaders roles recruitment diverse patient populations clinical trials vp us increase percentage support diverse communities black african american hispanic latinx vpand leaders year year assess performance least ethnically diverse leaders roles phase iii trials initiated proactive vp uk increase percentage plans place designed enrol appropriately diverse trial black vpandabove leaders year year participants consistent disease epidemiology improve yearonyear spend certified usbased diverse performance towards aspirations fair owned suppliers equitable opportunities women hold least vpandabove roles globally end diversity equity inclusion dei central purpose want inclusive workplace gsk people reflect getting ahead disease together inclusive communities operate leadership reflects diverse business business inclusively makes us gsk people helps company perform better successful making peoples potential brings better insights better quality decision making increasing positive impact want better health outcomes crucially helps us understand diverse patients make sure clinical trials reflect working make stem education equitable population affected disease increasing number underrepresented people stem careers focus us plans increase focus uk help ensure health innovators future diverse building inclusive business diseases disproportionately impact specific patient groups end gsk 's phase iii trials diversity safety efficacy medicines vaccines differ plan place enrol groups affected disease based genetic environmental factors therefore studied based epidemiology data example appropriate representation clinical research critical hepatitis b trials disease disproportionately affects people advancing understanding new medicines vaccines african asian descent participants asian ensure biggest impact patients origin actively working improve representation committed improving diversity clinical trial enrolment participants african descent already using disease insights set diversity enrolment goals g skcom approach clinical trials know barriers negatively impact clinical trial turnout certain patient populations access transportation strengthening supply chain supporting language differences lack trust awareness diverseowned suppliers working patient advocacy groups academic organisations tackle supplier diversity programme well established us expansion plan developed uk also collaborating regulators patients programme seek provide opportunities biopharma companies wider healthcare ecosystem represented groups including women ethnic minorities members together make meaningful progress diverse lgbt community people disabilities military participation clinical trials achieve shared goal better veterans well small businesses highunemployment health outcomes lowincome communities gsk esg performance report march approach access global health environment dei ethical standards product governance appendix diversity equity inclusion continued engage mentor small diverseowned businesses significantly exceeded combination supply chain help identify potential areas spend increases selected suppliers marketing sales growth target increase spend annually technology well identification new global diverse certified usbased diverseowned suppliers suppliers strong multiyear strategy engagement key advocacy groups nurturing people code requires people commit inclusive us ethnically diverse leaders vp aware impact others annual mandatory level reaching aspirational target least training creating inclusive workplace sets increasing percentage black african american standards expect hispanic latinx people roles year year uk ethnically diverse leaders vp g skcom code continuing make progress towards aspirational building diverse teams fair equitable target reaching least black representation vp remains flat focused efforts achieve opportunities aspiration yearonyear growth committed equality representation build representative workforce without workforce reflects communities work hire representative pool job applicants us engage gsk leadership reflects workforce historically black colleges universities hispanic committed increasing representation women serving institutions encourage applications graduate ethnically diverse people senior roles ensure positions target recruitment campaigns reach recruitment selection processes fair equitable represented groups managers committed building diverse inclusive g skcom gender pay gap report teams expect diverse shortlists gender ethnicity vacancies senior grades worked fostering inclusion workplaces recruitment agencies internal employee representation groups ergs specialist organisations continue gain insight working create inclusive workplace accessible support drive progress hiring managers required culture empathy acceptance complete inclusive interview training start embrace others differences identities selection process part work building future pipeline members uk governments disability confident accelerating difference programme supports development scheme launched threeyear plan increase women ethnically diverse leaders individual group disability confidence since gsk active coaching accelerating readiness future roles member valuable pledge grouping global women held vpandabove roles globally companies committed placing disability inclusion compared bringing us closer leadership agenda delivering schemes objectives aspirational target women made employees longterm measurable disability confidence plan management roles includes educating people issue remain committed improving application fair always looking better support people equitable pay practices ensure equal opportunities equal different life stages making sure offerings pay equal work conduct countrybased reviews fair inclusive introduced new global minimum ensure markets clear guidance tools support standard weeks parental leave primary secondary ensure pay equity unexplainable differences detected carers forms family new global minimum standard address compensation processes published care family member end life serious health sixth uk gender pay gap report gender pay gap emergencies insured benefits include sex partners permanent ukbased gsk employees mean wherever possible new financial wellbeing service mental compared national average health training available everyone published first uk ethnicity pay gap report using year recognised gold employer within stonewalls approach gender pay gap ethnicity pay gap top global employers index allyship programme received permanent ukbased gsk employees mean time award recognising tangible impact campaign national average comparator given commitment lives lgbt employees programme launched end diversity 're sharing uk ethnicity pay gap data based helps people become effective allies supporting approach gender pay gap recognising adjustments colleagues feel welcome valued included also achieved calculation methodology may required future human rights campaign foundations best places work lgbt equality standard countries meet criteria data confidentiality anonymity disclose race ethnicity people level set aspirational targets currently us uk meet criteria gsk esg performance report march approach access global health environment dei ethical standards product governance appendix diversity equity inclusion continued supporting diverse scientists future support communities around world global reached students nationwide health partnerships local community investment response committed investing million years humanitarian emergencies stem education programmes increase number women black latinx students underrepresented groups philadelphia entering stem careers local nonprofits received grants far gsk stem equity grants reached gsk science summer initiative offers free handson students stem learning students traditionally underrepresented groups stem careers underresourced communities us gender diversity women employees svpvp level pr director level manager level total women management women board share women stemrelated positions total stem positions women management positions revenuegenerating functions svpvp director manager employees us ethnic diversity american indian alaska native asian black african pr american hispanic latinx pr native hawaiian pacific islander two races ethnically pr diverse total white total uk ethnic diversity asian black pr mixed ethnically pr diverse total white total pr metric contributes esg performance rating metrics data externally assured w ith exception women board share women stemrelated positions women management positions revenuegenerating functions data displayed reflects gsk employees including aligned consumer healthcare business december reported year data represents actively responded identify gender category actively respond indicated prefer say data represents responded identify race ethnicity category us employees actively respond identify race ethnicity category indicated prefer say uk actively respond indicated prefer say due rounding sum data may marginally different totals nsufficient data report fewer three employees gsk esg performance report march approach access global health environment dei ethical standards product governance appendix ethical standards culture guides people right thing speak concerns important people live expect suppliers employees complementary employees believe direct highrisk suppliers workers completed speak achieved minimum mandatory training things n't feel right ecovadis score commitment promote ethical behaviour across business supporting percentage employees believe employees right thing working suppliers speak things dont feel right general share standards operate responsible way industry benchmark number employees leaving gsks employment assess performance misconduct last months versus threeyear employees complementary workers complete rolling average gsks mandatory training direct highrisk suppliers achieve gsks minimum ecovadis score improvement plan place supporting gsk people right thing expect everyone works us behalf reporting investigating concerns conducts right way builds trust anyone inside outside gsk raise concerns speak protects business helps create workplace integrity lines confidentially anonymously without fear thrive things important retaliation take every concern seriously review every launched new code conduct reflects report see whether need investigate formally purpose unite science technology talent get ahead investigations show employee breached policies disease together new code sets commitments take action make company deliver purpose year updated report breakdown ambitions code supported additional global types policy violations provide granularity case class policies standards located new code hub broader distribution top five policy area additionally people required complete categories historically reported saw overall accompanying global mandatory learning curriculum living decrease disciplinary cases attributed part revision code comprised three modules code creating procedures discipline regarding late completion inclusive workplace protecting gsk protecting gsk focuses mandatory training reported employee conduct key risk areas antibribery corruption abac category majority environment health safety ehs cyber security privacy around reporting human safety sustainability category increases written information related products well speak warnings related compliance company 's covid employees complementary workers vaccination mandate safety testing requirements ensure completed training due year end health safety wellbeing workforce certain highrisk roles geographic regions also continued embed greater focus use risk complete additional abac training helps identify analytics monitoring aligned increasing levels business mitigate potential abac risk especially thirdparty activities enhancing risk identification targeted interventions relationships recognise report manage additionally focused closure cases resulting conflicts interest employees decrease open cases year end prior years complementary workers completed training due correlation rising numbers employees dismissed year end agreed leave company voluntarily result approach managing abac risk risks relating misconduct ethical standards forms part well embedded risk management framework described detail annual report pages g skcom antibribery corruption policy code general industry benchmark according research kornferry gsk esg performance report march approach access global health environment dei ethical standards product governance appendix ethical standards continued upholding commitment human rights committed respecting internationally recognised committed application fair equitable pay human rights wherever business continue make practices includes ensuring employees globally progress integrating salient human rights access receive pay competitive local markets sufficient healthcare research practices patient safety ehs privacy support sustainable standard living completed within operations conduct business first global living wage review partnership fair wage foundation assessed pay employees signatories un global compact human people countries differences rights position statement lays commitment un detected fewer cases countries necessary guiding principles business human rights adjustments made end first quarter year established human rights steering group factoring living wage data standard formal reporting mechanism boards compensation processes ensure continue offer corporate responsibility committee steering group fair wage built annual living wage review comprises senior representatives key business functions standard cycle accountable ensuring respect human rights within information uphold commitments business area steering group facilitated human rights please refer modern slavery act statement attended external human rights experts g skcom position human rights modern slavery act statement developed guidance enhance supplier visits help employees better understand labour human rights noncompliances support guidance also developed delivered labour rights training ehs procurement employees better equip spot human rights issues visiting suppliers working third parties suppliers third parties including agents give additional support ehs risks largest suppliers distributors affiliate companies equity stake including supply globally medically critical products help us research develop manufacture distribute critical rd largest spend help medicines vaccines products patients need suppliers improve safety management systems build overall third parties act direct impact us ehs capability focusing active pharmaceutical ingredients important manage relationships well including manufacturers contract manufacturing suppliers set ehs way choose contract monitor requirements review performance part internal ehs governance oversight expect third parties meet abac labour rights standards relevant comply standards visit sites person virtually help suppliers better quality health safety environment see annual understand control risks relaxation travel report pages restrictions allowed us increase inperson visits identify reduce risk enabling us conduct physical visits across updated thirdparty risk management programme priority suppliers year completed warehouse safety evaluates mitigates risks introduced third parties surveys priority suppliers contract manufacturing engaged gsk provide goods services suppliers large warehouses hold stock year highrisk third parties determined location surveys generated corrective preventative action plans highrisk markets size spend performed expect complete assessments across risk areas assessments conducted supplier audits compared presented risks one areas third parties following industry standard pharmaceutical supply chain goods services providers distributors initiative guidelines corrective preventative actions wholesalers contract manufacturers suppliers tracked completion also trained direct material suppliers also use tools assess supplier employees ehs esg fundamentals suppliers manage risks including ecovadis desktop assessments revised ehs contractual obligations tracked management actions completion helped suppliers improve ecovadis scores see annual report g skcom position working third parties g sk maintains list globally medically critical products drug products approved treat lifethreatening disease medical condition adequately available alternative gsk provider ur ehs priority suppliers api suppliers medically rd revenuecritical gsk high spend suppliers supplier employees trained includes data previous consumer healthcare business gsk esg performance report march approach access global health environment dei ethical standards product governance appendix ethical standards continued data engagement exercise high standards integrity dealing using data responsibly personal information employees patients clinical research privacy ethical use data part global participants healthcare providers stakeholders mandatory learning curriculum living code people data security privacy landscape rapidly changing complete means understand everyone gsk threats cyber security constantly proliferating responsible handling personal information right way introduction privacy regulations national statelevel ensure key privacy personnel certifications authorities requires continual assessment review sufficient training experience carry roles effectively privacy framework controls response created investing artificial intelligence machine learning new digital privacy information security team within legal capability example help analyse patients genetic data compliance streamline support provide expertise mindful artificial intelligence machine learning around gsks digital data strategy global team raise ethical issues subject evolving decisions partner businesses assess impact changing policymakers best promote trust systems global local privacy regulations mitigate related risks avoid unintended outcomes harmful impacts see annual report pages rd oversight boards new advisory panel oversees controls manage use reuse data respond bioethical questions research activities makes sure follow regulations meet ethical obligations political engagement part heavily regulated industry business model political engagements committed ensuring market influenced legislation regulation adhere highest ethical standards legislative major multinational company seek contribute requirements make corporate political contributions public policy debate especially relation life sciences sponsor party political meetings anywhere around healthcare along stakeholders non world governmental organisations scientists healthcare professionals g skcom position political advocacy political advocacy disclosure patients industry groups frequently invited governments give views development new policies ethical conduct employees concerns raised including current year prior year open cases employees disciplined policy violations breakdown types policy violation employee conduct sales marketing product quality safeguarding people information assets employee relations hr policies rd medical practices antibribery corruption computer databreach security ehs sustainability pr metric contributes esg performance rating metrics data externally assured n updated reporting methodology breakdown types policy violation provide granularity case class broader distribution top five policy area categories historically reported 'other ' enable comparison prior year data restated using new reporting methodology n changed process circumstances trigger discipline late completion mandatory training reported employee conduct result saw fewer disciplinary cases compared prior years majority ehs sustainability category increases written warnings related compliance company 's covid vaccination mandate safety testing requirements ensure health safety wellbeing workforce p olicy violation class types fit class categories specified gsk esg performance report march approach access global health environment dei ethical standards product governance appendix ethical standards continued employees dismissed agreed leave company voluntarily result misconduct pr documented warnings open cases awaiting investigation disciplinary decision year end mandatory training employees complementary workers complete gsks mandatory training pr employees complete gsks mandatory training code living values expectations working gsk complementary workers complete gsks mandatory training code living values expectations working gsk employees complete gsks mandatory training abac complementary workers complete gsks mandatory training abac reporting concerns employees believe speak things dont feel right pr suppliers direct highrisk suppliers achieve gsks minimum ecovadis score pr improvement plan place supplier spend region asiapacific europe middle east africa latin america north america us political engagement spend federal lobbying activities trade association membership spend corporate political contributions political action committee contributions us employees state federal candidates ' european political engagement trade association membership spend corporate political contributions cost representing interests eu institutions pr metric contributes esg performance rating metrics data externally assured n continued embed greater focus use risk analytics monitoring aligned increasing levels business activities enhancing risk identification targeted interventions additionally focused closure cases resulting decrease open cases year end compared prior years correlation rising numbers employees dismissed agreed leave company voluntarily result misconduct hese figures based active employees complementary workers year end data split employees complementary workers disclosed prior esg reports rounded nearest whole number also includes data previous consumer healthcare business due attrition last three years restating completion rates would provide comparable metric updated way report completion mandatory training combining metrics employees complementary workers across mandatory trainings single metric rounded nearest whole number irect highrisk suppliers identified yearly basis combination spend category highrisk countries direct procurement involves purchasing materials directly associated production goods includes data previous consumer healthcare business g sk make corporate political contributions sponsor political meetings anywhere around world includes latest available figures previous year figures reporting year published march publication document gsk esg performance report march approach access global health environment dei ethical standards product governance appendix product governance ensuring quality safety reliable supply products critical protecting patients delivering health impact regulatory inspections quality audits clinical trial protocol manufacturing sites local suppliers summaries registered operating companies summaries results commitment commit maintaining robust quality safety processes number fda warning letters using data new technologies responsibly total number class iii external product recalls across markets assess performance register disclose human subject research gsk average number critical major findings products specifically register protocol summaries studies fdamhraema regulators initiated disclose results summaries studies percentage inspections regulators critical results due findings official action indicated quality safety products exceptionally important help us deliver reliable supply highquality products us systems place across gsk ensure meet support valuesdriven culture issues responded high standards set company swiftly transparently expected us externally focus quality management gsk quality management system detailed specific regulatory inspections manufacturing framework describes comply regulatory sites local operating companies compared requirements standards across markets remain prepared inspections regulators received addresses global local regulations across manufacturing warning letters united states food drugs distribution processes based principles defined administration fda critical findings medicines international council harmonisation technical healthcare products regulatory agency mhra european requirements pharmaceuticals human use medicines agency ema regulators however received one critical finding chinese regulator continue responsibility quality assurance managed gsk learn respond inspection findings taking quality organisations extensive global network quality necessary action address compliance professionals within business units sitelevel senior management throughout class product recalls fewer class ii iii recalls compared quality management system also details patient safety hesitate voluntarily recall products protect patients quality process training required gsk people includes induction hygiene safety technical skills training well working suppliers quality good distribution manufacturing practice training employees carry specific qualitycritical sensitive activities expect contract manufacturers suppliers comply subject additional checks necessary gsk standards regularly conduct audits verify conducted quality audits suppliers inspections recalls audit increased focus active pharmaceutical ingredient suppliers subject regulatory inspections markets supply comprehensive quality oversight model aligned products provide independent assurance high quality management system uses riskbased standards quality place across development manufacturing approach assess qualify manage monitor thirdparty distribution required maintain licence operate suppliers ongoing basis driving continuous performance w e consider observations us fda major c ritical finding one inspection chinese regulator thirdparty manufacturing facility used gsk c lass recalls triggered reasonable probability use exposure violative product cause serious adverse health consequences death class ii recalls address use exposure violative product may cause temporary medically reversible adverse health consequences probability serious adverse health consequences remote class iii recalls relate use exposure violative product likely cause adverse health consequences gsk esg performance report march approach access global health environment dei ethical standards product governance appendix product governance continued maintaining pharmacovigilance pharmacovigilance aims protect use medicines vigilance falsified medicines vaccines vaccines support public health programmes reliable robust approach handling falsified product comprehensive information overall benefitrisk balance incidents ensuring cases confirmed counterfeit products products well established rigorous worldwide reported relevant regulatory authorities system monitor review safety products actively participate legal proceedings illegal throughout clinical development regulatory approval actors provide regular training customs local authorities maintain high standards safety medical governance monitor online marketplaces social media request ensure partners meet expectations takedowns sites illicitly selling prescriptiononly medicines reviews thirdparty safety systems monitoring contractual g skcom position falsified substandard healthcare products obligations fostering collaboration life cycle relationship g skcom position pharmacovigilance committed transparency commitment transparency clinical trial data reflects part commitment made protocol wish help advance scientific understanding enable summaries summaries results available since scientific community learn research undertaken setup gsk trial register also listed also allows us acknowledge great contribution made studies data sharing via wwwvivliorg people take part clinical research wwwclinicalstudydatarequestcom regulatory inspections audits audits third parties quality processes total regulatory inspections health authorities pr inspections regulators critical findings official action indicated pr total regulatory inspections fdamhraema regulators pr number criticalmajor findings fdamhraema regulators pr total fda regulatory inspections pr number fda observations pr number fda warning letters pr product recalls total number class external product recalls pr total number class ii external product recalls pr total number class iii external product recalls pr total product recalls pr metric contributes esg performance rating metrics data externally assured includes data previous consumer healthcare business many audits conducted jointly consumer healthcare pharmaceuticals data point adjusted due eight additional inspections identified two inspections removed due retrospectively identified scope reporting criteria gsk esg performance report march approach access global health environment dei ethical standards product governance appendix product governance continued fda product recalls business class pharmaceuticals business class product recalls pr class ii product recalls pr class iii product recalls vaccines business class product recalls pr class ii product recalls pr class iii product recalls clinical trial management pharmacovigiliance transparency clinical trial audits trials conducted third parties behalf number fda sponsor inspections related clinical trial management pharmacovigilance resulted voluntary action indicated vai number fda sponsor inspections related clinical trial management pharmacovigilance resulted official action indicated oai clinical study reportsstudy report synopsis gsk study register trials anonymised data made available upon meeting defined eligibility criteria research teams approved access gsk trial data publicly available trial protocol summaries register pr publicly available trial result summaries disclose pr pr metric contributes esg performance rating metrics data externally assured data includes recalls us market may initiated voluntarily gsk requested us fda mandated us fda statutory authority represents total pharmaceutical products produced us market includes data previous consumer healthcare business making approximately figures hese figures cumulative gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix materiality assessment gsk conducted materiality assessment process process issues identified material engagement analysis identifies prioritises business external stakeholders illustrated esg issues pose significant risks opportunities matrix issues identified process helped business gsk significant impact confirm six esg focus areas access global health health materiality assessment used inform strategic decision security environment diversity equity inclusion ethical making helps us prioritise issues covered public reporting standards product governance year used datamarans data analytics platform read materiality methodology process conduct assessment software monitors external esg key observations please see materiality overview gskcom risks assessing coverage issues within peer annual g skcom materiality assessment sustainability reports regulatory legislative documents media social media also conducted stakeholder engagement internal external interviews analysis investor ratings rankings reports medium high importance business gsk esg performance report march sredlohekats lanretxe ot ecnatropmi materiality matrix high product quality privacy patient safety data security supply chain management product innovation global health security labour rights healthcare access affordability ethical business conduct employee health safety wellbeing clinical trial conduct climate change talent attraction retention nature environmental protection waste hazardous materials management diversity equity water wastewater management inclusion key access environment ethical standards global health diversity equity product governance health security inclusion people cultureour approach access global health environment dei ethical standards product governance appendix appendix continued people disclosures positive experience work critical attract retain keeping people safe motivate best people want workplace embrace care deeply health safety employees everyones unique differences encourage growth complementary workers everyone works visits development safe environment people perform sites commitment everyone goes home safely best work information around put life saving rules embedded throughout company people heart success please see rules simple standardised easy remember detail focus diversity equity inclusion responsibilities safety leaders individuals see reviewed levels organisation risk assessments key part environment health safety ehs freedom association control framework governs approach identifying respectful right colleagues join controlling hazards conduct health safety training independent trade union right collectively bargain people specific whether working office freedom association global employees covered lab manufacturing site commercial recent key collective bargaining arrangements declared initiatives included safety leadership warehouse safety member union gsk also invests heavily driver safety formal information consultation arrangements actively g skcom environment health safety policy involve provide additional employee voice higher proportion colleagues hiring total number new hires open positions filled internal candidates employee turnover overall turnover turnover voluntary leavers permanent leavers male permanent leavers female workforce breakdown age permanent employees years old years old years old engagement employee surveys engagement score employee surveys response rate talent leadership development number graduates recruited future leaders programme number postgraduates recruited esprit programme number apprentices recruited metrics data externally assured n certain markets data unavailable due privacy reasons c alculated number permanent employees voluntarily left gsk divided average permanent headcount c alculated number permanent employees left gsk reason within period male female divided total number permanent leavers left reason within period engagement data derived gsk annual survey total employee base invited participate engagement data derived q pulse survey statisticallyrelevant randomised sample population representing average gsk employee invited participate employee surveys engagement score reported consistent methodology used across two types survey derive comparable engagement score however employee surveys response rate reported methodology used administer pulse surveys subsequent response rate comparable used gsk annual survey includes responses aligned previous consumer healthcare business gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued health safety number fatalities employees complementary workers gsk direct supervision number fatalities contractors gsk direct supervision reportable injuries lost time reportable illnesses lost time lost time reportable injury rate per hours worked lost time reportable illness rate per hours worked reportable injuries without lost time reportable illnesses without lost time reportable injury rate per hours worked reportable illness rate per hours worked reportable injury illness rate per hours worked hours worked metrics data externally assured totals may equal exact sum constituents due rounding gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued gri guidelines sasb index gri indicator description find information general disclosures organisational details legal name gsk plc ownership annual report share capital share price hq address brentford middlesex tw gs uk operations annual report business model entities included organisations sustainability reporting gsk plc reporting period frequency contact point sustainability financial annual reporting period january december report publication march contact csrcontactgskcom restatements information demerger comparative results restated reflect demerger consumer healthcare business unless otherwise specified restatements information detailed relevant specific data points throughout report external assurance independent limited assurance statements pages activities value chain business relationships sector healthcare pharmaceuticals annual report business model changes compared previous reporting period following demerger consumer healthcare business form haleon july fully focused biopharma company employees fulltime employees ftes december annual report employees gender changes compared previous reporting period following demerger consumer healthcare business form haleon july fullyfocused biopharma company workers employees reported governance structure composition annual report board gsk leadership team annual report corporate governance architecture annual report nominations corporate governance nomination selection highest governance body committee report chair highest governance body gsk independent nonexecutive chair board role highest governance body overseeing annual report corporate responsibility committee report management impacts delegation responsibility managing impacts annual report corporate responsibility committee report role highest governance body sustainability reporting esg performance report reviewed gsk leadership team board conflicts interest annual report directors conflicts interest communication critical concerns annual report board committee reports collective knowledge highest governance body annual report board evaluation performance highest governance body annual report board performance remuneration policies annual report annual report remuneration process determine remuneration annual report annual report remuneration annual total compensation ratio annual report annual report remuneration statement sustainable development strategy annual report ceo 's statement policy commitments policy positions including human rights policies approved gsk leadership team level apply grouplevel embedding policy commitments corporate responsibility committee processes remediate negative impacts annual report principal risks uncertainties ethical standards ethics compliance grievance mechanisms gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued gri indicator description find information mechanisms seeking advice raising concerns ethical standards grievance mechanisms compliance laws regulations annual report audit risk committee report membership associations trade association memberships approach stakeholder engagement materiality assessment collective bargaining agreements people disclosures pages position human rights process determine material topics materiality assessment list material topics materiality assessment management material topics materiality assessment economic performance direct economic value generated distributed annual report financial statements financial implications risks opportunities due annual report risk management climate change annual report tcfd defined benefit plan obligations retirement plans annual report annual report remuneration financial assistance received government annual report financial statements annual report share capital share price anticorruption operations assessed risks related corruption annual report risk management communication training anticorruption policies ethical standards pages procedures confirmed incidents corruption actions taken ethical standards pages tax approach tax gsk tax strategy tax governance control risk management gsk tax strategy stakeholder engagement management concerns gsk tax strategy related tax countrybycountry reporting gsk tax strategy energy energy consumption within organisation environment pages environment basis reporting energy consumption outside organisation environment pages environment basis reporting energy intensity annual report risk management environment basis reporting reduction energy consumption environment pages environment basis reporting reductions energy requirements products services environment pages environment basis reporting water interactions water shared resource environment pages management water dischargerelated impacts environment basis reporting water withdrawal environment pages environment basis reporting water discharge environment pages environment basis reporting water consumption environment pages environment basis reporting gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued gri indicator description find information emissions direct scope ghg emissions environment pages environment basis reporting energy indirect scope ghg emissions environment pages environment basis reporting indirect scope ghg emissions environment pages environment basis reporting ghg emissions intensity annual report tcfd environment basis reporting reduction ghg emissions environment pages environment basis reporting emissions ozonedepleting substances ods environment pages environment basis reporting nitrogen oxides nox sulfur oxides sox significant reported air emissions waste waste generation significant wasterelated impacts environment pages management significant wasterelated impacts environment pages environment basis reporting waste generated environment pages environment basis reporting waste diverted disposal environment pages environment basis reporting waste directed disposal environment pages supplier environmental assessment new suppliers screened using environmental ethical standards pages criteria negative environmental impacts supply chain ethical standards pages actions taken employment new employee hires employee turnover people disclosures pages benefits provided fulltime employees life gsk provided temporary parttime employees parental leave reported occupational health safety occupational health safety management system gsk ehs policy hazard identification risk assessment incident gsk ehs policy investigation occupational health services gsk ehs policy worker participation consultation communication gsk ehs policy occupational health safety worker training occupational health safety gsk ehs policy promotion worker health gsk ehs policy prevention mitigation occupational health safety gsk ehs policy impacts directly linked business relationships workers covered occupational health safety gsk ehs policy management system workrelated injuries people disclosures pages gsk ehs policy workrelated ill health gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued gri indicator description find information diversity equal opportunity diversity governance bodies employees diversity equity inclusion pages people disclosures pages ratio basic salary remuneration women men gender pay gap report diversity equity inclusion human rights labour rights operations suppliers right freedom gsk position human rights association collective bargaining may risk operations suppliers significant risk incidents gsk position human rights child labour modern slavery act statement operations suppliers significant risk incidents gsk position human rights forced compulsory labour modern slavery act statement new suppliers screened using social criteria ethical standards pages negative social impacts supply chain actions ethical standards pages taken public policy political contributions political advocacy disclosure customer health safety assessment health safety impacts product product governance pages service categories incidents noncompliance concerning health product governance pages safety impacts products services marketing labelling requirements product service information code practice labelling incidents noncompliance concerning product service product governance pages information labelling incidents noncompliance concerning marketing product governance pages communications sasb indicator description find information drug safety hcbpa list products listed food drug administrations available via fda fda medwatch safety alerts human medical products database hcbpa number fatalities associated products reported available via fda fda adverse event reporting system hcbpa number fda recalls issued total units recalled product governance pages hcbpa total amount product accepted takeback reuse reported disposal hcbpa number fda enforcement actions taken response product governance pages violations current good manufacturing practices cgmp type counterfeit drugs hcbpa description methods technologies used maintain product governance pages traceability products throughout supply chain position falsified prevent counterfeiting substandard healthcare products hcbpa discussion process alerting customers business product governance pages partners potential known risks associated position falsified counterfeit products substandard healthcare products hcbpa number actions led raids seizure arrests andor reported filing criminal charges related counterfeit products gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued sasb indicator description find information ethical marketing hcbpa total amount monetary losses result legal reported proceedings associated false marketing claims hcbpa description code ethics governing promotion code practice promotional nonpromotional external offlabel use products interactions employee recruitment development retention hcbpa discussion talent recruitment retention efforts approach pages scientists research development personnel hcbpa voluntary involuntary turnover rate people disclosures pages executivessenior managers b midlevel managers c professionals others supply chain management hcbpa percentage entitys facilities tier suppliers gsk member rx facilities participating rx international also conducts audits third pharmaceutical supply chain consortium audit programme parties equivalent thirdparty audit programmes integrity product governance pages supply chain ingredients business ethics hcbpa total amount monetary losses result legal reported proceedings associated corruption bribery hcbpa description code ethics governing interactions engagement healthcare professionals healthcare professionals activity metrics hcbpa number patients treated access pages patients reached access strategies hcbpb number drugs portfolio research annual report pipeline products competition development phases gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued list products list prequalified medicinal products vaccines part prequalification medicines programme pqp type form presentation date prequalification vaccines engerix hepatitis b liquid ready use vial one dose thursday january engerix hepatitis b liquid ready use vial doses thursday january engerix hepatitis b liquid ready use vial doses thursday january priorix measles mumps rubella lyophilised active component reconstituted friday march excipient diluent use vial one dose rotarix rotavirus liquid ready use plastic tube one dose thursday march rotarix rotavirus liquid ready use applicator one dose thursday march cervarix human papillomavirus bivalent liquid ready use vial one dose wednesday july cervarix human papillomavirus bivalent liquid ready use vial two doses wednesday july polio sabin mono polio vaccine oral opv monovalent type liquid ready use vial doses thursday october polio sabin mono polio vaccine oral opv monovalent type liquid ready use vial doses thursday october polio sabin one three polio vaccine oral opv bivalent types liquid ready use vial doses thursday october polio sabin one three polio vaccine oral opv bivalent types liquid ready use vial doses thursday october synflorix pneumococcal conjugate liquid ready use vial one dose friday october synflorix pneumococcal conjugate liquid ready use vial two doses friday march polio sabin mono three oral polio vaccine oral opv monovalent type liquid ready use vial doses tuesday october polio sabin mono three oral polio vaccine oral opv monovalent type liquid ready use vial doses tuesday october polio sabin mono two oral polio vaccine oral opv monovalent type liquid ready use vial doses wednesday may polio sabin mono two oral polio vaccine oral opv monovalent type liquid ready use vial doses wednesday may priorix measles mumps rubella lyophilised active component reconstituted wednesday december excipient diluent use vial two doses hepatitis human diploid cell inactivated adult liquid ready use vial havrix adult friday july one dose havrix junior hepatitis human diploid cell inactivated paediatric liquid ready use vial friday july one dose boostrix diphtheriatetanuspertussis acellular liquid ready use vial one dose tuesday july menveo meningococcal acyw conjugate vaccine lyophilised active component wednesday july reconstituted liquid active component use two vial set one dose synflorix pneumococcal conjugate liquid ready use vial four doses monday october rotarix rotavirus liquid ready use plastic tube five doses thursday february mosquirix plasmodium falciparum malaria hepatitis b recombinant adjuvanted friday july liquid active component mixed second component use two vial set two doses pharmaceuticals abacavir sulfate hiv viiv healthcare ha march abacavir sulfate hiv viiv healthcare ha march zidovudine hiv viiv healthcare ha may zidovudine hiv viiv healthcare ha may lamivudinezidovudine hiv viiv healthcare ha march zidovudine hiv viiv healthcare ha march zidovudine hiv viiv healthcare ha march lamivudine hiv viiv healthcare ha march lamivudine hiv viiv healthcare ha march dolutegravir sodium hiv viiv healthcare ha october abacavir sulfatelamivudine hiv viiv healthcare ha june dolutegravir sodium hiv viiv healthcare ha july zanamivir influenza gsk september gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued esg reporting criteria unless stated otherwise data reflects reporting period january december kpi definition method access total community donations made gsk globally donations included voluntary charitable purpose investment charitable purposes including cash product donations valued gbp yearend exchange rates inkind donations value time donated via product donations valued global average cost goods reported philadelphia stem equity collective yearend results management costs associated charitable programmes inkind donations valued value cost item gsk current external purchase price previous years data included comparison restated inflation exchange rate changes methodology used follows bsi formerly lbg framework corporate community investment value gsk medicine value medicine vaccines provided gsk viiv patient assistance programs foundation administers vaccines provided gsk viiv healthcare patient patient assistance programs patients us puerto rico us us patient assistance programs foundation provides virgin islands assistance program medication charge eligible individuals capture patient assistance program orders gsk viiv cogs million usd patients receive medications healthcare products internal ordering database data patient assistance programs must meet captured according wholesale acquisition cost medicine eligibility requirements requirements vaccine coded free good charitable orders amount include insurance status financial component converted cost goods sold amount reporting purposes based federal poverty level patient participation varies annually based current program eligibility resident us puerto rico us virgin criteria overall healthcare environmental factors products included islands treated uslicensed programs healthcare provider doses rotarix number doses rotarix synflorix calculate number doses supplied use number gsk synflorix cervarix cervarix vaccine supplied gavi doses shipped gavi supported countries vaccines supplied vaccine alliance gsk gavi supplier since gavis inception gavi millions doses opv number doses opv vaccine calculate number doses supplied use number gsk vaccines supplied supplied unicef doses shipped countries procuring via unicef unicef millions doses mosquirix number doses mosquirix rtss calculate number doses supplied use number gsk rtssas e e vaccine donated malaria vaccine doses procured unicef mvips procurement agent shipped vaccines supplied implementation programme mvip mvip countries ghana kenya malawi mvip gsk supplying mosquirix rtssas e first millions malaria vaccine since beginning mvip albendazole tablets number albendazole tablets donated albendazole tablet shipments sent gsks manufacturing facility donated help world health organization support endemic countries shipments entered realtime database eliminate lymphatic endemic country efforts eliminate lymphatic donated medicines neglected tropical diseases albendazole tablet filariasis millions filariasis donation figures lymphatic filariasis aggregated reported annually data pulled system albendazole tablets number albendazole tablets donated albendazole tablet shipments sent gsks manufacturing facility donated help treat world health organization support endemic countries shipments entered realtime database intestinal worms endemic country efforts treat soiltransmitted donated medicines neglected tropical diseases albendazole tablet millions helminthiasis intestinal worms schoolage donation figures soiltransmitted helminthiasis control aggregated children reported annually data pulled system people access total number people living hiv chronic ongoing treatment capture cumulative number generic dolutegravir currently accessing generic dolutegravirbased people access dolutegravir rather annual data avoid product products viiv healthcares voluntary duplication indicator therefore represents total number people voluntary licensing licensing agreements medicines patent living hiv accessing treatment time measurement agreements pool directly aurobindo pharma lifelong treatment number incorporates people receiving ongoing treatment multiple years number calculated adding total number packs generic dolutegravirbased products sold previous four quarters divided twelve obtain average monthly sales estimate number people treatment packs converted pack equivalents ie monthly equivalents daily treatment data provided medicines patent pool aurobindo viivs dolutegravir patents sublicensed gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued kpi definition method access estimated children estimated number children calculate estimated number children reached use number reached synflorix received synflorix vaccine prevention gsk doses shipped gavi supported countries divide gavi pneumococcal infection gavi number doses needed complete full schedule gavi estimated vaccine alliance vaccine wastage rates factored synflorix full schedule three children receiving synflorix five doses gavi estimates wastage years age see detailedproductprofilesxlsx livecom estimated children estimated number children calculate estimated number children reached use number reached rotarix received rotarix vaccine prevention gsk doses shipped gavi supported countries divide gavi rotavirus gavi vaccine alliance number doses needed complete full schedule gavi estimated children receiving rotarix five years vaccine wastage rates factored rotarix full schedule two doses age gavi estimates wastage see detailedproductprofilesxlsx livecom estimated girls estimated number girls calculate estimated number girls reached use number gsk reached cervarix received cervarix vaccine prevention doses shipped gavi supported countries divide number gavi cervical cancer gavi vaccine doses needed complete full schedule gavi estimated vaccine alliance wastage rates factored cervarix full schedule two doses gavi estimates wastage see detailedproductprofilesxlsx livecom estimated people estimated number people calculate estimated number people reached use number reached oral received opv vaccine polio procured bivalent opv bopv monovalent opv mopv doses shipped polio vaccine opv unicef unicef divided number doses needed complete full unicef schedule estimated vaccine wastage rates factored outbreak situations gsk opv volumes often used one dose usually given child however primary schedule four doses children may receive one dose subsequent outbreak campaigns use four doses calculation order conservative estimates wastage given supply dose vials vials mainly used campaigns vials may may used discarded vial opened end session see indicative vaccine wastage rates revisingwastageconceptnotepdf whoint estimated people estimated number children calculate estimated number children reached use number reached received mosquirix rtssas e vaccine gsk doses shipped mvip countries ghana kenya malawi divide mosquirix rtssas malaria vaccine implementation number doses needed complete full schedule four doses e mvip programme mvip estimated vaccine wastage rates two dose vials used ' routine immunisation factored see indicative vaccine wastage rates revisingwastageconceptnotepdf whoint people reached total number unique individuals gsk viiv patient assistance programs foundation administers us patient received gsk viiv healthcare product patient assistance programs patients us puerto rico us assistance programs patient assistance programs virgin islands patients receive medications us patient assistance programs provides report year end patient assistance programs must meet eligibility enables us consolidate number unique patients received requirements requirements include gsk viiv healthcare products throughout year insurance status financial component based patient participation varies annually based current program eligibility federal poverty level resident criteria overall healthcare environmental conditions products included us puerto rico us virgin islands programs treated uslicensed healthcare provider gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued kpi definition method global health health security number assets number assets progressed pipeline progression defined movement global health asset progressed global health pipeline address priority one phase another gsk recognises progression global health diseases across gsks two global health hubs following four categories pipeline address tres cantos spain focuses senior leadership endorsement business plan progression priority diseases therapeutics gsk vaccines institute clinical trial starts first subject first visitdose global health gvgh sienna focuses business developmentinlicensing preventative treatment regulatory milestone ie submission approval launch priority diseases defined diseases pathogens prioritized rd public health emergency contexts distinguishes diseases degree pose greatest public health risk due epidemic potential andor whether insufficient countermeasures gsk uses following lists priority pathogen list emergency diseases list blueprint prioritized disease list essential medicines list un sustainable development goals reviews updates lists needs arise methodologies change environment full list environment reporting criteria please see basis reporting including full definitions methodologies diversity equity inclusion gender diversity percentage women broken data covers total number employees identify women within svpvp director manager employees hr system including active fulltimeparttime regulartemporary total percentage women employees nonactive ie maternity leave paternity leave management 'management ' classed adoption leave etc excludes agency temporary workers contingent employee grade bands includes workers defined payrolled via recruitment agencies employees managers directors vps svps gender recorded indicated prefer say percentage calculated using employee numbers december recorded hr system gender specified female within grades divided total employees system us uk ethnic percentage ethnically diverse employees data covers total number employees internal hr system diversity gsk us uk employee population active including fulltimeparttime regulartemporary employees across svpvp level director level manager nonactive ie maternity leave paternity leave adoption leave level across employees etc excludes puerto ricobased employees agency temporary workers due differing ethnic groups across uk contingent workers defined payrolled via recruitment agencies us employee population raceethnic employees blank ethnicity prefer say us figures categories defined according uk census exclude puerto ricobased employees given significant differences ethnic us federal reporting guidelines composition territorys population relative rest us percentage calculated using employee numbers december recorded hr system selfidentified ethnically diverse divided total employees system ethical standards employees number distinct employees anyone inside outside gsk raise concerns speak concerns raised disciplinary concern raised independent third party integrity lines confidentially anonymously concerns also raised internally employees including current management internal monitoring year prior year data comprises regular employees excludes contractors open cases contingent workers data includes total number distinct employees disciplinary concern raised reporting period employees disciplinary concerns raised prior years open cases employees disciplined number distinct employees data comprises regular employees excludes contractors policy violations outcome concern raised resulted contingent workers disciplinary action data represents cases closed reporting period also included three open cases disciplinary decisions made action taken year end however cases yet closed source system reporting criteria end date range due timing disciplinary action includes documented warning termination resignation gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued kpi definition method ethical standards breakdown types breakdown types policy violations data comprises regular employees excludes contractors policy violation employees disciplined contingent workers year individual employees subject multiple allegations resulting policy violations categories defined disciplinary action case individual counted unique category antibribery corruption antibribery corruption employee discipline results policy violation includes level cyber security cyber security csir sanction level sanction level sanction final warning termination continuity supply chain supply chain resignation categorised appropriate outcomes employees continuity including mediation demotion settlement included counts ehs sustainability environment health percentages within categories outcome types considered safety sustainability disciplinary action represent situations employees employee conduct conflict interest company work together towards solution discrimination expenses harassment markets except germany utilise case management system inappropriate behaviour mandatory training manage cases data retention german market maintains employee relations hr policies case list submitted global employee relations team year appeal attendance work capability health end consolidation analysis capability performance external litigation gsk case owners regularly utilise published data quality reports assist performance system recruitment selection data accuracy regularly quarterly internal audits conducted restructuring programmes settlementmutual address outstanding data discrepancies agreement working arrangements government trade restrictions sanctions export controls product quality good manufacturing practice manufacturing site resilience supply chain quality assurance research development medical practices care welfare treatment animals data integrity nongxp good laboratory practicesgood clinical practice human biological sample management hbsm nonpromotional engagement nonpromotional engagement patient safety public disclosure regulatory filings safeguard people information assets communications corporate financial information reporting disclosure crisis continuity management fraud intellectual property privacy loss data privacy unauthorized access privacy unsecured data disclosure protection physical assets security security people security places sites security productssupply chain sales marketing antitrust commercial practices funding contract sales organisation external experts hcphci transfer value inappropriate managerial direction interactions pagsconsumerpayer groups product promotion samples speaker programme tax treasury tax treasury policy violation types fit categories specified employees number distinct employees data comprises regular employees excludes contractors dismissed agreed outcome disciplinary concern resulted contingent workers leave company termination employment voluntary data represents cases closed reporting period voluntarily result resignation employee also included three open cases disciplinary decisions made misconduct action taken year end however cases yet closed source system reporting criteria end date range due timing includes termination employment resignation documented warnings number distinct employees data comprises regular employees excludes contractors outcome disciplinary concern resulted contingent workers documented warning data represents cases closed reporting period also included three open cases disciplinary decisions made action taken year end however cases yet closed source system reporting criteria end date range due timing disciplinary action includes documented warning level sanction final warning gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued kpi definition method ethical standards open cases awaiting number distinct employees involved data comprises regular employees excludes contractors investigation investigation disciplinary decision contingent workers disciplinary decision still open pending outcome data represents employees involved disciplinary case year end end reporting period remain open end reporting period also included three open cases disciplinary decisions made action taken year end however cases yet closed source system reporting criteria end date range due timing outcome investigations still open awaiting disciplinary action year end captured subsequent reporting period employees percentage active employees andor active employees fulltimeparttime regulartemporary complementary complementary workers complementary workers ie agency workers statement work workers workers complete assigned mandatory training curriculum outsourced workers etc required complete global mandatory gsks mandatory completed training modules learning curriculum called living code comprises three modules training code protecting gsk creating inclusive workplace additionally highrisk roles geographic regions complete additional module focusing antibribery corruption percentage calculated using training data december ie training due december calculated total number active employees complementary workers assigned living code mandatory training completed modules divided total population active employees complementary workers assigned living code mandatory training employees percentage employees strongly pulse surveys issued q q q different third believe agreed agreed question organisation targeted survey entire employee speak things speak things dont feel right gsk population gsk reached score calculated using average n't feel right pulse survey score across surveys survey issued regular fulltime fixedterm contract employees countries gsk operates excluding russia ukraine questions translated professional service partners languages excluding english direct highrisk direct highrisk suppliers identified ecovadis programme work direct highrisk suppliers suppliers achieve yearly basis combination spend help improve operations support sustainability gsks minimum category highrisk countries direct journey ecovadis score procurement involves purchasing ecovadis external ratings provider assesses organisations across improvement materials directly associated four themes environment community labour human rights ethics plan place production goods sustainable procurement total number direct supplier may improvement plan place suppliers highrisk managed assessment progress supplier committed participate gsks ecovadis programme programme hasnt commenced yet supplier hasnt accepted improvement plan place defined improvement plan improvement plan implemented ongoing improvement plan supplier awaits reassessment reflect improved score gsk requires suppliers minimum reported supplier improvement plan place ecovadis score improvement plan initiated supplier partners including gsk tracked ecovadis platform required gsk interacts directly supplier ensure corrective actions implemented ecovadis scorecard data exported ecovadis platform five suppliers manually adjusted group subsidiary based business relationship gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued kpi definition method product governance total regulatory number regulatory inspections gsk data represents good manufacturing practise gmpgood inspections entities health authorities distribution practice gdp inspections results confirmed health authorities inspections percentage number regulatory percentage across gmpgdp results confirmed regulators inspections gsk entities critical percentage calculated total number inspections critical findings findings official action indicated regulators critical findings official action indicated divided official action total number inspections regulators multiplied indicated total regulatory number regulatory inspections number regulatory inspections across gmpgdp inspections based inspections following regulators gsk entities fda mhra european regulators national competent authorities fdamhraema united states food drugs administration inspecting behalf ema regulatory bodies results regulators us fda united kingdom uk medicines confirmed healthcare products regulatory agency mhra european medicines agency ema national competent authority eea regulators number critical number critical major findings number critical major findings across gmpgdp business major findings regulatory inspections gsk entities us products based us fda mhra european regulators fdamhraema fda uk mhra ema regulators inspecting behalf ema regulatory bodies results regulators confirmed total fda regulatory total number regulatory inspections number regulatory inspections across gmpgdp business inspections gsk entities us fda products based us fda regulatory inspections results confirmed fda define inspections onsite therefore paperbased assessments oneoff questions excluded fda number fda number observations issued number findings across gmpgdp business products observations us fda gsk entities based us fda regulatory inspections results confirmed number fda number warning letters issued number gmpgdp warning letters warning letters us fda gsk entities led enforced regulatory actions required total number number external class iiiiii recalls number external class iiiiii recalls across gmpgdp class iiiiii external product broken recall type product recalls class recall reasonable probability use exposure violative product cause serious adverse health consequences death class ii recall use exposure violative product may cause temporary medically reversible adverse health consequences probability serious adverse health consequences remote class iii recall use exposure violative product likely cause adverse health consequences data includes recalls may initiated gsk mandated regulators fda product recalls number recalls product us business units track recalls respective systems business class market includes recalls may initiated voluntarily gsk mandated us fda fda order statutory authority categorise data according businesses relates pharmaceuticals vaccines according recall type gsk esg performance report march approach access global health environment dei ethical standards product governance appendix appendix continued kpi definition method product governance publicly available trial number trial protocol summaries report cumulative number studies protocols protocol summaries registered external facing gsk trial registered results disclosed since setup gsk trial register register register wwwgskstudyregistercom part gsks internal policy commitment studies protocol summaries registered results disclosure human subject research summaries disclosed gsk available gsk trial register addition mandatory requirements wwwgskstudyregistercom regulators disclosure protocol registrations numbers represent studies initiated protocol registered completed studies results publicly available trial number trial results summaries posted summaries due numbers generated result summaries external facing gsk trial register transparency report derives data disclosure system disclose wwwgskstudyregistercom part gsks used business internal policy commitment disclosure human subject research addition mandatory requirements regulators disclosure results summaries people disclosures overall turnover overall turnover measure gsk calculate number leavers year percentage employees leaving gsk include average permanent headcount internal moves within gsk employee turnover rate includes employees left company data include divestments voluntarily involuntarily year including employees divested data updated daily extracted gskwide hr platform consumer health business data based effective date termination termination date termination date last day work effective date termination first day termination ie following day therefore employees termination dates december included dataset health safety gsk reportable injury illness meets consistent global reporting gsk injury illness meets data following criteria listed criteria criteria different national regulatory reporting reportable injury affected individual either gsk requirements vary across world illness including employee worker direct gsk daily fatalities supervision incident workrelated outcome involved least one following fatality loss consciousness medical treatment beyond first aid significant occupational injury occupational illness diagnosed physician licensed healthcare professional days away workrestricted daysjob transfer must new case lost time lost time incident one resulted lost time days counted day following incident either days away work job transfer restriction employee unable perform one routine activities hours worked total number hours worked hours worked calculated based number working days year employees including full time employees length average workday number employees site directly supervised agency staff provided gsk human resources gsk esg performance report march independent limited assurance report directors gsk plc gskplcgskcommissioneddnvbusinessassuranceservicesuklimiteddnvusorwetoconductalimitedassuranceengagementover selectedinformationpresentedintheesgperformancereportthereportforthereportingyearendeddecember conclusion based procedures performed evidence obtained nothing come attention causes us believe selected informationisnotfairlystatedandhasnotbeenpreparedinallmaterialrespectsinaccordance withthecriteria thisconclusionrelatesonlytotheselectedinformationandistobereadinthecontextofthis independentlimitedassurancereportinparticulartheinherentlimitationsexplainedoverleaf observations areas improvement raised separate report gsks management selectedinformation scope boundary work restricted key performance indicators competence independence includedwithinthereportforthecurrentreportingyeartheselectedinformationlisted quality control theenvironmentalsocialandgovernanceesgperformancedataincludedwithinthe reporttheselectedinformationforthereportingyearlistedinappendixof dnv established policies procedures thisdocument designedtoensurethatdnvitspersonneland theoverallesgperformanceratingscorerelatingtogsksperformanceagainst applicable others subject targetsaslistedonpagesofgsksesgperformancereport independence requirements including personnel entities dnv assess theselected information includes assessment risk material maintain independence required misstatementinthereportwehaveusedgsksreportingcriteriaesgdatacollectionand relevant ethical requirements controlprocessesandesgperformanceratingthecriteriaasummaryofwhichcanbe engagement work carried foundonpagesandofthereport independent team sustainability assurance professionals multidisciplinary team performed work express conclusion consisted professionals combination information may published report gsks website current environmental social sustainability reportingperiodorforpreviousperiods assuranceexperience standardandlevelofassurance inherent limitations performed limited assurance engagement accordance international standardonassuranceengagementsisaerevisedassuranceengagementsother audits reviews historical financial information revised issued assurance engagements subject international auditing assurance standards board standard requires inherent limitations selective testing comply ethical requirements plan perform assurance engagement samplingmaynotdetecterrorsfraudorother obtainlimitedassurance irregularitiesnonfinancialdatamaybesubject greater inherent uncertainty financial dnvappliesitsownmanagementstandardsandcompliancepoliciesforqualitycontrolin data given nature methods used accordance isoiec conformity assessment requirements bodies calculating estimating determining providing audit certification management systems accordingly maintains datatheselectionofdifferentbutacceptable comprehensive system quality control including documented policies procedures measurement techniques may result regardingcompliancewithethicalrequirementsprofessionalstandardsandapplicablelegal different quantifications different andregulatoryrequirements entities assurance relies premise procedures performed limited assurance engagement vary nature timing data information provided us gsk fromandarelessinextentthanforareasonableassuranceengagementandthelevelof provided good faith dnv assuranceobtainedissubstantiallylowerthantheassurancethatwouldhavebeenobtained expressly disclaims liability co hadareasonableassuranceengagementbeenperformedweplannedandperformedour responsibility decision person worktoobtaintheevidenceweconsideredsufficienttoprovideabasisforourconclusion entity may make based assurance sothattheriskofthisconclusionbeinginerrorisreducedbutnotreducedtoverylow statement gsk esg performance report march basisofourconclusion responsibilities directors required plan perform work order consider riskof material gsk dnv misstatementoftheselectedinformationourworkincludedbutwasnotrestrictedto assessingtheappropriatenessofthecriteriafortheselectedinformation conductinginterviewswithgsksmanagementtoobtainanunderstandingofthekey thedirectorsofgskhavesoleresponsibility processessystemsandcontrolsinplacetogenerateaggregateandreporttheselected information preparing presenting selected performinglimitedsubstantivetestingonaselectivebasisoftheselectedinformationto information accordance checkthatdatahadbeenappropriatelymeasuredrecordedcollatedandreported criteria recalculatingtheselectedinformationasestablishedbygskscriteria designingimplementingandmaintaining reviewinginformationprovidedbygsksthirdpartycontractors effective internal controls reviewingthattheevidencemeasurementsandthescopeprovidedtousbygskforthe information data resulting selectedinformationispreparedinlinewiththecriteria preparation selected information readingthereportandnarrativeaccompanyingtheselectedinformationwithinitwith thatisfreefrommaterialmisstatements regardtothecriteria measuring reporting selected information based established criteriaand contents statements contained withinthereportandthecriteria ourresponsibilityistoplanandperformour work obtain limited assurance whether selected information preparedinaccordancewiththecriteriaand report gsk form independent limited assurance conclusion based work performed evidence obtained responsibleforthepreparationofthereport dnv business assurance dnvbusinessassuranceservicesuklimited londonuk dnvbusinessassuranceservicesuklimited march ispartofdnvbusinessassuranceaglobal provider certification verification assessment training services helping customers build sustainable business performance wwwdnvcoukbetterassurance gsk esg performance report march appendix selected information access total number class ii external product recalls people reached product reach target total number class iii external product recalls people access generic dolutegravir product fda product recalls business class voluntary licensing agreements pharmaceuticals business estimated children reached synflorixthrough gavi ' class product recalls estimated children reached rotarix gavi ' class ii product recalls estimated girls reached cervarixthrough gavi ' class iii product recalls vaccines business estimated people reached opv unicef ' class product recalls estimated people reached mosquirixrtssas e class ii product recalls mvip ' class iii product recalls total people reached register disclose human subject research gsk products doses synflorixvaccines supplied gavi million publicly available trial protocol summaries register doses rotarix vaccines supplied gavi million publicly available trial result summaries disclose doses cervarixvaccines supplied gavi million ethical standards doses opv vaccines supplied unicef million employees cws complete gsk 's mandatory doses mosquirixrtssas e vaccines supplied mvip training million employees believe speak things albendazole tablets donated help eliminate lymphatic filariasis n't feel right millions direct highrisk suppliers achieving ecovadisscore albendazole tablets donated help treat intestinal worms millions improvement plan place community investment employees leaving gsk 's employment misconduct last total community investment million months cash million employees concerns raised including current product inkind million year prior year open cases time million employees disciplined policy violations management costs million breakdown types policy violation people reached us patient assistance program ' employee conduct value gsk medicine vaccines provided us patient sales marketing assistance programs foundation million usd product quality global health health security safeguarding people information assets number assets progressed global health pipeline employee relations address priority diseases research development medical practices inclusion diversity antibribery corruption us ethnic diversity broken svpvp director manager computer data breach security employees ehs sustainability ethnically diverse total employees dismissed agreed leave company uk ethnic diversity broken svpvp director manager voluntarily result misconduct employees ethnically diverse total documented warnings open cases awaiting investigation disciplinary decision year gender diversity broken svpvp director manager end employees total women management people disclosures number fatalities employees complementary workers governance gsk direct supervision product governance fatalities contractors gsk direct supervision regulatory inspections reportable injuries lost time total regulatory inspections health authorities reportable illnesses lost time inspections regulators critical findings lost time reportable injury rate official action indicated lost time reportable illness rate total regulatory inspections fdamhraema regulators reportable injuries without lost time number criticalmajor findings fdamhraema regulators reportable illnesses without lost time total fda regulatory inspections reportable injury rate number fda observations reportable illness rate number fda warning letters reportable injury illness rate hours worked product recalls overall turnover total product recalls total number class external product recalls gsk esg performance report march iinnddeeppeennddeenntt lliimmiitteedd aassssuurraannccee rreeppoorrtt ttoo tthhee ddiirreeccttoorrss ooff ggsskk ppllcc independent limited assurance report deloitte llp directors gsk plc selected environmental social governance esg metrics selected information within annual report accounts environmental social governance esg performance report year ending december wwhhaatt wwee ffoouunndd oouurr aassssuurraannccee ccoonncclluussiioonn based procedures described report evidence obtained nothing come attention causes us believe selected information listed indicated annual report accounts esg performance report prepared material respects accordance applicable criteria defined basis reporting prepared published gsk plc esg resources gsk wwhhaatt wwee llooookkeedd aatt ssccooppee ooff oouurr wwoorrkk rreevviisseedd aass ppeerr tthhee ootthheerr mmaatttteerrss sseeccttiioonn bbeellooww gsk plc engaged us provide independent limited assurance accordance international standard assurance engagements revised assurance engagements audits reviews historical financial information isae revised international standard assurance engagements assurance engagements greenhouse gas statements isae issued international auditing assurance standards board iaasb agreed terms engagement selected information scope engagement listed indicated annual report accounts esg performance report follows selected information units assured value scope emissions tonnes co e scope emissions market based tonnes co e scope emissions location tonnes co e based total scope market based tonnes co e emissions total energy operations gwh purchased renewable electricity gwh onsite renewably generated gwh electricity emissions use propellant tonnes co e based inhalers patients total water use high water risk cubic metres sites total wastewater discharged cubic metres total water use cubic metres gsk esg performance report march selected information listed tableneeds read understood together applicable criteria set basis reporting esg resources gsk iinnhheerreenntt lliimmiittaattiioonnss ooff tthhee sseelleecctteedd iinnffoorrmmaattiioonn obtained limited assurance preparation selected information accordance applicable criteria inherent limitations exist assurance engagements internal control structure matter effective eliminate possibility fraud errors irregularities may occur remain undetected use selective testing engagement guarantee errors irregularities present detected applicable criteria defined gsk plc within basis reporting nature selected information absence consistent external standards allow different acceptable measurement methodologies adopted may result variances entities adopted measurement methodologies may also impact comparability selected information reported different organisations year year within organisation methodologies develop ootthheerr mmaatttteerrss initial selected information scope engagement included waste metrics defined course work became clear would unable obtain evidence needed support conclusion respect waste metrics described management concluded significant remediation required measurement reporting waste metrics asked us remove scope engagement waste metrics defined total circular waste total waste generated tonnes total waste recovered circular route tonnes total waste sent landfill tonnes ddiirreeccttoorrss rreessppoonnssiibbiilliittiieess directors responsible preparing annual report accounts complies requirements companies act satisfied annual report accounts esg performance report taken whole fair balanced understandable directors also responsible making available necessary records correspondence information explanations necessary allow successful completion services selecting andor establishing suitable criteria preparing selected information measuring reporting selected information accordance applicable criteria designing implementing maintaining internal processes controls information relevant preparation selected information free material misstatement whether due fraud error taking reasonable steps prevention detection fraud irregularities gsk esg performance report march oouurr rreessppoonnssiibbiilliittiieess responsible independently expressing conclusion whether based assurance procedures anything come attention causes us believe selected information set prepared material respects accordance applicable criteria year ended december oouurr iinnddeeppeennddeennccee aanndd ccoommppeetteennccee conducting engagement complied independence requirements frcs ethical standard icaew code ethics icaew code founded fundamental principles integrity objectivity professional competence due care confidentiality professional behaviour applied international standard quality management isqm issued financial reporting council accordingly maintained comprehensive system quality including documented policies procedures regarding compliance ethical requirements professional standards applicable legal regulatory requirements wwhhaatt wwee ddiidd kkeeyy pprroocceedduurreess required plan perform work address areas identified material misstatement description activities undertaken respect selected information likely arise procedures performed based professional judgement carrying limited assurance engagement description activities undertaken respect selected information performed following procedures performed enquires interviews management understand applicable criteria applied preparation selected information understood internal controls quantification process data used preparing selected information methodology gathering qualitative information process preparing reporting selected information inspected documents relating selected information including board committee minutes understand level management awareness oversight selected information considered risk material misstatement selected information including analytical review procedures performed procedures selected information including recalculation relevant formulae used manual calculations assessment whether data appropriately consolidated performed procedures underlying data sample basis assess whether data collected reported accordance applicable criteria including verifying source documentation performed procedures selected information including assessing managements assumptions estimates performed site visit selection operational sites understand processes place read reports narrative accompanying selected information regard applicable criteria consistency findings accumulated misstatements control deficiencies identified assessed whether material procedures performed limited assurance engagement vary nature timing less extent reasonable assurance engagement consequently level assurance gsk esg performance report march obtained limited assurance engagement substantially lower assurance would obtained reasonable assurance engagement performed uussee ooff oouurr rreeppoorrtt report made solely directors gsk plc accordance isae revised isae agreed terms engagement work undertaken might state directors gsk plc matters agreed state report purpose without assuming accepting responsibility liability respect report party gsk plc directors gsk plc acknowledge directors gsk plc may choose make report publicly available others wishing access affect extend purpose basis responsibilities fullest extent permitted law accept assume responsibility anyone gsk plc directors gsk plc body work report conclusions formed ddeellooiittttee llllpp london uk march gsk esg performance report march